header logo image


Page 1,127«..1020..1,1261,1271,1281,129..1,1401,150..»

Gut flora – Wikipedia, the free encyclopedia

August 4th, 2016 9:36 am

Gut flora (gut microbiota, or gastrointestinal microbiota) is the complex community of microorganisms that live in the digestive tracts of humans and other animals, including insects. The gut metagenome is the aggregate of all the genomes of gut microbiota.[1] The gut is one niche that human microbiota inhabit.[2]

In humans, the gut microbiota has the largest numbers of bacteria and the greatest number of species compared to other areas of the body.[3] In humans the gut flora is established at one to two years after birth, and by that time the intestinal epithelium and the intestinal mucosal barrier that it secretes have co-developed in a way that is tolerant to, and even supportive of, the gut flora and that also provides a barrier to pathogenic organisms.[4][5]

The relationship between gut flora and humans is not merely commensal (a non-harmful coexistence), but rather a mutualistic relationship.[2]:700 Human gut microorganisms benefit the host by collecting the energy from the fermentation of undigested carbohydrates and the subsequent absorption of short-chain fatty acids (SCFAs), acetate, butyrate, and propionate.[3][6] Intestinal bacteria also play a role in synthesizing vitamin B and vitamin K as well as metabolizing bile acids, sterols, and xenobiotics.[2][6] The systemic importance of the SCFAs and other compounds they produce are like hormones and the gut flora itself appears to function like an endocrine organ,[6] and dysregulation of the gut flora has been correlated with a host of inflammatory and autoimmune conditions.[3][7]

The composition of human gut flora changes over time, when the diet changes, and as overall health changes.[3][7]

The microbial composition of the gut flora varies across the digestive tract. In the stomach and small intestine, relatively few species of bacteria are generally present.[8][9] The colon, in contrast, contains a densely-populated microbial ecosystem with up to 1012 cells per gram of intestinal content.[8] These bacteria represent between 300 and 1000 different species.[8][9] However, 99% of the bacteria come from about 30 or 40 species.[10] As a consequence of their abundance in the intestine, bacteria also make up to 60% of the dry mass of feces.[11]Fungi, archaea, and viruses are also present in the gut flora, but less is known about their activities.[12]

Over 99% of the bacteria in the gut are anaerobes, but in the cecum, aerobic bacteria reach high densities.[2] It is estimated that these gut flora have around a hundred times as many genes in aggregate as there are in the human genome.[13]

Many species in the gut have not been studied outside of their hosts because most cannot be cultured.[9][10][14] While there are a small number of core species of microbes shared by most individuals, populations of microbes can vary widely among different individuals.[15] Within an individual, microbe populations stay fairly constant over time, even though some alterations may occur with changes in lifestyle, diet and age.[8][16] The Human microbiome project has set out to better describe the microflora of the human gut and other body locations.

The four dominant phyla in the human gut are Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria.[17] Most bacteria belong to the genera Bacteroides, Clostridium, Faecalibacterium,[8][10]Eubacterium, Ruminococcus, Peptococcus, Peptostreptococcus, and Bifidobacterium.[8][10] Other genera, such as Escherichia and Lactobacillus, are present to a lesser extent.[8] Species from the genus Bacteroides alone constitute about 30% of all bacteria in the gut, suggesting that this genus is especially important in the functioning of the host.[9]

The currently known genera of fungi of the gut flora include Candida, Saccharomyces, Aspergillus, and Penicillium.

Archaea constitute another large class of gut flora which are important in the metabolism of the bacterial products of fermentation.

An enterotype is a classification of living organisms based on its bacteriological ecosystem in the human gut microbiome not dictated by age, gender, body weight, or national divisions.[18] There are indications that long-term diet influences enterotype.[19] Three human enterotypes have been discovered.[18][20]

Due to the high acidity of the stomach, most microorganisms cannot survive. The main bacterial inhabitants of the stomach include: Streptococcus, Staphylococcus, Lactobacillus, Peptostreptococcus, and types of yeast.[2]:720Helicobacter pylori is a Gram-negative spiral organism that establishes on gastric mucosa causing chronic gastritis and peptic ulcer disease and is a carcinogen for gastric cancer.[2]:904

The small intestine contains a trace amount of microorganisms due to the proximity and influence of the stomach. Gram positive cocci and rod shaped bacteria are the predominant microorganisms found in the small intestine.[2] However, in the distal portion of the small intestine alkaline conditions support gram-positive bacteria of the Enterobacteriaceae.[2] The bacterial flora of the small intestine aid in a wide range of intestinal functions. The bacterial flora provide regulatory signals that enable the development and utility of the gut. Overgrowth of bacteria in the small intestine can lead to intestinal failure.[21] In addition the large intestine contains the largest bacterial ecosystem in the human body.[2] Factors that disrupt the microorganism population of the large intestine include antibiotics, stress, and parasites.[2]

Bacteria make up most of the flora in the colon[22] and 60% of the dry mass of feces.[8] This fact makes feces an ideal source to test for gut flora for any tests and experiments by extracting the nucleic acid from fecal specimens, and bacterial 16S rRNA gene sequences are generated with bacterial primers. This form of testing is also often preferable to more invasive techniques, such as biopsies. Somewhere between 300[8] and 1000 different species live in the gut,[9] with most estimates at about 500.,[23][24] However, it is probable that 99% of the bacteria come from about 30 or 40 species, with Faecalibacterium prausnitzii being the most common species in healthy adults.[10][25]Fungi and protozoa also make up a part of the gut flora, but little is known about their activities.

Research suggests that the relationship between gut flora[26] and humans is not merely commensal (a non-harmful coexistence), but rather is a mutualistic, symbiotic relationship.[9] Though people can (barely) survive with no gut flora,[23] the microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system via end products of metabolism like propionate and acetate, preventing growth of harmful species, regulating the development of the gut, producing vitamins for the host (such as biotin and vitamin K), and producing hormones to direct the host to store fats.[2]:713ff Extensive modification and imbalances of the gut microbiota and its microbiome or gene collection are associated with obesity.[27] However, in certain conditions, some species are thought to be capable of causing disease by causing infection or increasing cancer risk for the host.[8][22]

It has been demonstrated that there are common patterns of microbiome composition evolution during life.[29] In general, the diversity of microbiota composition of fecal samples is significantly higher in adults than in children, although interpersonal differences are higher in children than in adults.[30] Much of the maturation of microbiota into an adult-like configuration happens during the three first years of life.[30]

As the microbiome composition changes, so does the composition of bacterial proteins produced in the gut. In adult microbiomes, a high prevalence of enzymes involved in fermentation, methanogenesis and the metabolism of arginine, glutamate, aspartate and lysine have been found. In contrast, in infant microbiomes the dominant enzymes are involved in cysteine metabolism and fermentation pathways.[30]

Studies and statistical analyses have identified the different bacterial genera in gut microbiota and their associations with nutrient intake. Gut microflora is mainly composed of three enterotypes: Prevotella, Bacteroides, and Ruminococcus. There is an association between the concentration of each microbial community and diet. For example, Prevotella is related to carbohydrates and simple sugars, while Bacteroides is associated with proteins, amino acids, and saturated fats. One enterotype will dominate depending on the diet. Altering the diet will result in a corresponding change in the numbers of species.[19]

Malnourished human children have less mature and less diverse gut microbiota than healthy children, and changes in the microbiome associated with nutrient scarcity can in turn be a pathophysiological cause of malnutrition.[31][32] Malnourished children also typically have more potentially pathogenic gut flora, and more yeast in their mouths and throats.[33]

Gut microbiome composition depends on the geographic origin of populations. Variations in trade off of Prevotella, the representation of the urease gene, and the representation of genes encoding glutamate synthase/degradation or other enzymes involved in amino acids degradation or vitamin biosynthesis show significant differences between populations from USA, Malawi or Amerindian origin.[30]

The US population has a high representation of enzymes encoding the degradation of glutamine and enzymes involved in vitamin and lipoic acid biosynthesis; whereas Malawi and Amerindian populations have a high representation of enzymes encoding glutamate synthase and they also have an overrepresentation of -amylase in their microbiomes. As the US population has a diet richer in fats than Amerindian or Malawian populations which have a corn-rich diet, the diet is probably a main determinant of gut bacterial composition.[30]

Further studies have indicated a large difference in the composition of microbiota between European and rural African children. The fecal bacteria of children from Florence were compared to that of children from the small rural village of Boulpon in Burkina Faso. The diet of a typical child living in this village is largely lacking in fats and animal proteins and rich in polysaccharides and plant proteins. The fecal bacteria of European children was dominated by Firmicutes and showed a marked reduction in biodiversity, while the fecal bacteria of the Boulpon children was dominated by Bacteroidetes. The increased biodiversity and different composition of gut flora in African populations may aid in the digestion of normally indigestible plant polysaccharides and also may result in a reduced incidence of non-infectious colonic diseases.[34]

On a smaller scale, it has been shown that sharing numerous common environmental exposures in a family is a strong determinant of individual microbiome composition. This effect has no genetic influence and it is consistently observed in culturally different populations.[30]

In humans, a gut flora similar to an adult's is formed within one to two years of birth.[4] The gastrointestinal tract of a normal fetus has been considered to be sterile, however recently it has been acknowledged that microbial colonisation may occur in the fetus.[35] During birth and rapidly thereafter, bacteria from the mother and the surrounding environment colonize the infant's gut.[4] As of 2013, it was unclear whether most of colonizing arise from the mother or not.[4] Infants born by caesarean section may also be exposed to their mothers' microflora, but the initial exposure is most likely to be from the surrounding environment such as the air, other infants, and the nursing staff, which serve as vectors for transfer.[36] During the first year of life, the composition of the gut flora is generally simple and it changes a great deal with time and is not the same across individuals.[4]

The initial bacterial population are generally facultative anaerobic organisms; investigators believe that these initial colonizers decrease the oxygen concentration in the gut, which in turn allows purely aneorobic bacteria like Bacteroides, Actinobacteria, and Firmicutes to become established and thrive.[4] Breast-fed babies become dominated by bifidobacteria, possibly due to the contents of bifidobacterial growth factors in breast milk.[37][38] In contrast, the microbiota of formula-fed infants is more diverse, with high numbers of Enterobacteriaceae, enterococci, bifidobacteria, Bacteroides, and clostridia.[39]

Bacteria in the gut fulfill a host of useful functions for humans, including digestion of unutilized energy substrates,[40] stimulating cell growth, repressing the growth of harmful microorganisms, training the immune system to respond only to pathogens, and defending against some diseases.[8][9][41]

Without gut flora, the human body would be unable to utilize some of the undigested carbohydrates it consumes, because some types of gut flora have enzymes that human cells lack for breaking down certain polysaccharides.[6] Rodents raised in a sterile environment and lacking in gut flora need to eat 30% more calories just to remain the same weight as their normal counterparts.[6] Carbohydrates that humans cannot digest without bacterial help include certain starches, fiber, oligosaccharides, and sugars that the body failed to digest and absorb like lactose in the case of lactose intolerance and sugar alcohols, mucus produced by the gut, and proteins.[3][6]

Bacteria turn carbohydrates they ferment into short-chain fatty acids (SCFAs)[10][24] by a form of fermentation called saccharolytic fermentation.[24] Products include acetic acid, propionic acid and butyric acid.[10][24] These materials can be used by host cells, providing a major source of useful energy and nutrients for humans,[24] as well as helping the body to absorb essential dietary minerals such as calcium, magnesium and iron.[8] Gases and organic acids, such as lactic acid, are also produced by saccharolytic fermentation.[10] Acetic acid is used by muscle, propionic acid helps the liver produce ATP, and butyric acid provides energy to gut cells and may prevent cancer.[24] Evidence also indicates that bacteria enhance the absorption and storage of lipids[9] and produce and then facilitate the body to absorb needed vitamins like vitamin K.

Another benefit of SCFAs is that they increase growth of intestinal epithelial cells and control their proliferation and differentiation.[8] They may also cause lymphoid tissue near the gut to grow. Bacterial cells also alter intestinal growth by changing the expression of cell surface proteins such as sodium/glucose transporters.[9] In addition, changes they make to cells may prevent injury to the gut mucosa from occurring.[41]

In humans, a gut flora similar to an adult's is formed within one to two years of birth.[4] As the gut flora gets established, the lining of the intestines - the intestinal epithelium and the intestinal mucosal barrier that it secretes - develop as well, in a way that is tolerant to, and even supportive of, commensurate microorganisms to a certain extent and also provides a barrier to pathogenic ones.[4] Specifically, goblet cells that produce the muscosa proliferate, and the mucosa layer thickens, providing an outside mucosal layer in which "friendly" microorganisms can anchor and feed, and an inner layer that even these organisms cannot penetrate.[4][5] Additionally, the development of gut-associated lymphoid tissue (GALT), which forms part of the intestinal epithelium and which detects and reacts to pathogens, appears and develops during the time that the gut flora develops and established.[4] The GALT that develops is tolerant to gut flora species, but not to other microorganisms.[4] GALT also normally becomes tolerant to food to which the infant is exposed, as well as digestive products of food, and gut flora's metabolites produced from food.[4]

The human immune system creates cytokines that can drive the immune system to produce inflammation in order to protect itself, and that can tamp down the immune response to maintain homeostasis and allow healing after insult or injury.[4] Different bacterial species that appear in gut flora have been shown to be able to drive the immune system to create cytokines selectively; for example Bacteroides fragilis and some Clostridia species appear to drive an anti-inflammatory response, while some segmented filamentous bacteria drive the production of inflammatory cytokines.[4][42] Gut flora can also regulate the production of antibodies by the immune system.[4][43] These cytokines and antibodies can have effects outside the gut, in the lungs and other tissues.[4]

The resident gut microflora positively control the intestinal epithelial cell differentiation and proliferation through the production of short-chain fatty acids. They also mediate other metabolic effects such as the syntheses of vitamins like biotin and folate, as well as absorption of ions including magnesium, calcium and iron.[16]Methanogenic archae such as Methanobrevibacter smithii are involved in the removal of end products of bacterial fermentation such as hydrogen.[2]

Altering the numbers of gut bacteria, for example by taking broad-spectrum antibiotics, may affect the host's health and ability to digest food.[44] Antibiotics can cause antibiotic-associated diarrhea (AAD) by irritating the bowel directly, changing the levels of gut flora, or allowing pathogenic bacteria to grow.[10] Another harmful effect of antibiotics is the increase in numbers of antibiotic-resistant bacteria found after their use, which, when they invade the host, cause illnesses that are difficult to treat with antibiotics.[44]

Changing the numbers and species of gut flora can reduce the body's ability to ferment carbohydrates and metabolize bile acids and may cause diarrhea. Carbohydrates that are not broken down may absorb too much water and cause runny stools, or lack of SCFAs produced by gut flora could cause the diarrhea.[10]

A reduction in levels of native bacterial species also disrupts their ability to inhibit the growth of harmful species such as C. difficile and Salmonella kedougou, and these species can get out of hand, though their overgrowth may be incidental and not be the true cause of diarrhea.[8][10][44] Emerging treatment protocols for C. difficile infections involve fecal microbiota transplantation of donor feces. (see Fecal transplant). Initial reports of treatment describe success rates of 90%, with few side effects. Efficacy is speculated to result from restoring bacterial balances of bacteroides and firmicutes classes of bacteria.[45]

Gut flora composition also changes in severe illnesses, due not only to antibiotic use but also to such factors as ischemia of the gut, failure to eat, and immune compromise. Negative effects from this have led to interest in selective digestive tract decontamination (SDD), a treatment to kill only pathogenic bacteria and allow the re-establishment of healthy ones.[46]

Antibiotics alter the population of the gastrointestinal (GI) tract microbiota, may change the intra-community metabolic interactions, modify caloric intake by using carbohydrates, and globally affects host metabolic, hormonal and immune homeostasis.[47]

Probiotics are microorganisms that are believed to provide health benefits when consumed.[48][49] With regard to gut flora, prebiotics are typically non-digestible, fiber compounds that pass undigested through the upper part of the gastrointestinal tract and stimulate the growth or activity of advantageous gut flora by acting as substrate for them.[24][50]

Synbiotics refers to food ingredients or dietary supplements combining probiotics and prebiotics in a form of synergism.[51]

The term "pharmabiotics" is used in various ways, to mean: pharmaceutical formulations (standardized manufacturing that can obtain regulatory approval as a drug) of probiotics, prebiotics, or synbiotics;[52] probiotics that have been genetically engineered or otherwise optimized for best performance (shelf life, survival in the digestive tract, etc.);[53] and the natural products of gut flora metabolism (vitamins, etc.).[54]

There is some evidence that treatment with some probiotic strains of bacteria may be effective in irritable bowel syndrome and chronic idiopathic constipation. Those organisms most likely to result in a decrease of symptoms have included:

Gram positive bacteria present in the lumen may be associated with extending the duration of relapse for ulcerative colitis.[56]

Women's gut microbiota change as pregnancy advances, with the changes similar to those seen in metabolic syndromes such as diabetes. The change in gut flora causes no ill effects. The newborn's gut biota resemble the mother's first-trimester samples. The diversity of the flora decreases from the first to third trimester, as the numbers of certain species go up.[58]

Weight loss initiates a shift in the bacteria phyla that compose gut flora. Specifically, Bacteroidetes increase nearly linearly as weight loss progresses.[59] While there is a high level of variation in bacteria species found among individual people, this trend is prominent and distinct in humans.[60]

Bacteria in the digestive tract can contribute to disease in various ways. The presence or overabundance of some kinds of bacteria may contribute to inflammatory disorders such as inflammatory bowel disease.[8] Additionally, metabolites from certain members of the gut flora may influence host signaling pathways, contributing to disorders such as obesity and colon cancer.[8] Alternatively, in the event of a breakdown of the gut epithelium, the intrusion of gut flora components into other host compartments can lead to sepsis.[8]

Some genera of bacteria, such as Bacteroides and Clostridium, have been associated with an increase in tumor growth rate, while other genera, such as Lactobacillus and Bifidobacteria, are known to prevent tumor formation.[8]

As the liver is fed directly by the portal vein, whatever crosses the intestinal epithelium and the intestinal mucosal barrier enters the liver, as do cytokines generated there.[61] Dysbiosis in the gut flora has been linked with the development of cirrhosis and non-alcoholic fatty liver disease.[61]

Normally-commensal bacteria can be very harmful to the host if they get outside of the intestinal tract.[4][5]Translocation, which occurs when bacteria leave the gut through its mucosal lining, the border between the lumen of the gut and the inside of the body, can occur in a number of different diseases, and can be caused by too much growth of bacteria in the small intestine, reduced immunity of the host, or increased gut lining permeability.[5]

If the gut is perforated, bacteria can invade the body, causing a potentially fatal infection. Aerobic bacteria can make an infection worse by using up all available oxygen and creating an environment favorable to anaerobes.[2]:715

In a similar manner, Helicobacter pylori can cause stomach ulcers by crossing the epithelial lining of the stomach. Here the body produces an immune response. During this response parietal cells are stimulated and release extra hydrochloric acid (HCl+) into the stomach. However, the response does not stimulate the mucus-secreting cells that protect and line the epithelium of the stomach. The extra acid sears holes into the epithelial lining of the stomach, resulting in stomach ulcers.[29]

Inflammatory bowel diseases, Crohn's disease and ulcerative colitis, are all chronic inflammatory disorders of the gut, and asthma and diabetes have been described as inflammatory disorders as well; the causes of these disease are unknown and issues with the gut flora and its relationship with the host have been implicated in these conditions.[7][62][63][64]

Two hypotheses have been posed to explain the rising prevalence of these diseases in the developed world: the hygiene hypothesis, which posits that children in the developed world are not exposed to a wide enough range of pathogens and end up with an overreactive immune system, and the role of the Western pattern diet which lacks whole grains and fiber and has an overabundance of simple sugars.[7] Both hypotheses converge on the changes in the gut flora and its role in modulating the immune system, and as of 2016 this was an active area of research.[7]

Similar hypotheses have been posited for the rise of food and other allergies.[65]

As of 2016 it is not clear if changes to the gut flora cause these auto-immune and inflammatory disorders or are a product of them or adaptation to them.[7][66]

The gut flora has also been implicated in obesity and metabolic syndrome due to the key role it plays in the digestive process; the Western pattern diet appears to drive and maintain changes in the gut flora that in turn change how much energy is derived from food and how that energy is used.[64][67]

Aside from mammals, some insects also possess complex and diverse gut microbiota that play key nutritional roles.[68] Microbial communities associated termites can constitute a majority of the weight of the individuals and perform important roles in the digestion of lignocellulose and nitrogen fixation.[69] These communities are host-specific, and closely related insect species share comparable similarities in gut microbiota composition.[70][71] In cockroaches, gut microbiota have been shown to assemble in a deterministic fashion, irrespective of the inoculum;[72] the reason for this host-specific assembly remains unclear. Bacterial communities associated with insects like termites and cockroaches are determined by a combination of forces, primarily diet, but there is some indication that host phylogeny may also be playing a role in the selection of lineages.[70][71]

For more than 51 years we have known that the administration of low doses of antibacterial agents promotes the growth of farm animals to increase weight gain.[47]

In a study performed on mice by Ilseung Cho,[47] the ratio of Firmicutes and Lachnospiraceae was significantly elevated in animals treated with subtherapeutic doses of different antibiotics. By analyzing the caloric content of faeces and the concentration of small chain fatty acids (SCFAs) in the GI tract, they concluded that the changes in the composition of microbiota lead to an increased capacity to extract calories from otherwise indigestible constituents, and to an increased production of SCFAs. These findings provide evidence that antibiotics perturb not only the composition of the GI microbiome but also its metabolic capabilities, specifically with respect to SCFAs.[47]

More:
Gut flora - Wikipedia, the free encyclopedia

Read More...

Fasting for three days can regenerate entire immune system …

August 4th, 2016 9:36 am

Fasting for as little as three days can regenerate the entire immune system, even in the elderly, scientists have found in a breakthrough described as "remarkable".

Although fasting diets have been criticised by nutritionists for being unhealthy, new research suggests starving the body kick-starts stem cells into producing new white blood cells, which fight off infection.

Scientists at the University of Southern California say the discovery could be particularly beneficial for people suffering from damaged immune systems, such as cancer patients on chemotherapy.

It could also help the elderly whose immune system becomes less effective as they age, making it harder for them to fight off even common diseases.

The researchers say fasting "flips a regenerative switch" which prompts stem cells to create brand new white blood cells, essentially regenerating the entire immune system.

"It gives the 'OK' for stem cells to go ahead and begin proliferating and rebuild the entire system," said Prof Valter Longo, Professor of Gerontology and the Biological Sciences at the University of California.

"And the good news is that the body got rid of the parts of the system that might be damaged or old, the inefficient parts, during the fasting.

Now, if you start with a system heavily damaged by chemotherapy or ageing, fasting cycles can generate, literally, a new immune system."

Prolonged fasting forces the body to use stores of glucose and fat but also breaks down a significant portion of white blood cells.

During each cycle of fasting, this depletion of white blood cells induces changes that trigger stem cell-based regeneration of new immune system cells.

In trials humans were asked to regularly fast for between two and four days over a six-month period.

Scientists found that prolonged fasting also reduced the enzyme PKA, which is linked to ageing and a hormone which increases cancer risk and tumour growth.

"We could not predict that prolonged fasting would have such a remarkable effect in promoting stem cell-based regeneration of the hematopoietic system," added Prof Longo.

"When you starve, the system tries to save energy, and one of the things it can do to save energy is to recycle a lot of the immune cells that are not needed, especially those that may be damaged," Dr Longo said.

"What we started noticing in both our human work and animal work is that the white blood cell count goes down with prolonged fasting. Then when you re-feed, the blood cells come back. So we started thinking, well, where does it come from?"

Fasting for 72 hours also protected cancer patients against the toxic impact of chemotherapy.

"While chemotherapy saves lives, it causes significant collateral damage to the immune system. The results of this study suggest that fasting may mitigate some of the harmful effects of chemotherapy," said co-author Tanya Dorff, assistant professor of clinical medicine at the USC Norris Comprehensive Cancer Center and Hospital.

"More clinical studies are needed, and any such dietary intervention should be undertaken only under the guidance of a physician.

"We are investigating the possibility that these effects are applicable to many different systems and organs, not just the immune system," added Prof Longo.

However, some British experts were sceptical of the research.

Dr Graham Rook, emeritus professor of immunology at University College London, said the study sounded "improbable".

Chris Mason, Professor of Regenerative Medicine at UCL, said: There is some interesting data here. It sees that fasting reduces the number and size of cells and then re-feeding at 72 hours saw a rebound.

That could be potentially useful because that is not such a long time that it would be terribly harmful to someone with cancer.

But I think the most sensible way forward would be to synthesize this effect with drugs. I am not sure fasting is the best idea. People are better eating on a regular basis.

Dr Longo added: There is no evidence at all that fasting would be dangerous while there is strong evidence that it is beneficial.

I have received emails from hundreds of cancer patients who have combined chemo with fasting, many with the assistance of the oncologists.

Thus far the great majority have reported doing very well and only a few have reported some side effects including fainting and a temporary increase in liver markers. Clearly we need to finish the clinical trials, but it looks very promising.

Follow this link:
Fasting for three days can regenerate entire immune system ...

Read More...

Tampa Stem Cell Therapy | PRP | Knee | Joint Replacement …

August 4th, 2016 9:36 am

Featured in the News Across the Nation: Dr. Dennis Lox, an Expert in Sports & Regenerative Medicine, Discusses Knee Stem Cell Therapy, Hip Stem Cell Therapyand Ankle Stem Cell Therapy.

Since 1990, Dennis M. Lox, M.D. has been helping patients increase their quality of life by reducing their pain. He emphasizes non-surgical treatments and appropriate use of medications, if needed.

Many patients are turning to stem cell therapy as a means of nonsurgical joint pain relief when their mobility and quality of life are severely affected by conditions like osteoarthritis, torn tendons, and injured ligaments. Dennis M. Lox, M.D. specializes in this progressive, innovative treatment that may be able to help you return to an active, fulfilling life.

Each week, Dr. Dennis Lox receives inquiries from aroundthe worldregarding stem cell therapy.

TRAVEL ARRANGEMENTS CAN BE MADE FOR YOU LOCAL OR INTERNATIONAL

Visit our Press Room

Stem cell therapy for joint injuries and osteoarthritis is suited for many individuals, fromprofessional athletes to active seniors. Adult mesenchymal stem cells, not embryonic stem cells, are used in this procedure, which is performed right in the comfort of Dr. Loxs state-of-the-art clinic. The cells are simply extracted from the patients own body (typically from bone marrow or adipose/ fat tissue), processed in our office, and injected directly into the site of injury. Conditions that can be addressed with stem cell treatment include osteoarthritis, degenerative disc disease, knee joint issues (such as meniscus tears), shoulder damage (such as rotator cuff injuries), hip problems (such as labral tears), and tendonitis, among others. For many patients, a stem cell procedure in the knee, hip, shoulder, or another area of the body relieves pain, increases mobility, and may be able to delay or eliminate the need for more aggressive treatments like joint replacement surgery.

If you have questions about adult stem cell therapy for joint injuries and arthritis, how the procedure is performed, and how the stem cells work to repair injured joints and tissues, Dr. Lox would be happy to educate you about the entire process.

If you are searching for effective, nonsurgical joint replacement alternatives, regenerative therapies like stem cell treatments and PRP therapy may be the ideal solution. At Florida Spine and Sports Medicine, we focus on helping patients return to mobile, independent lives without the need for the risks and downtime associated with highly invasive surgery.PRP Therapy, Stem Cell Treatments & Other Joint Replacement Alternatives for Patients in Tampa, Clearwater, New Port Richey & throughout the U.S.A. and the world.

PRP (platelet rich plasma) therapy can be used alone, or adult stem cell therapy is often used in conjunction with PRP as a means of promoting healing in degenerated or injured joints, cartilage, muscles, and tendons. From knee pain to spine pain, there are a wide range of conditions that may respond to these forms of regenerative medicine. Some of the most common issues that Dr. Lox treats at Florida Spine and Sports Medicine include knee arthritis, meniscal tears, S/I joint pain, hip conditions, shoulder pain, and ankle pain, among others.

If you live in Clearwater, St. Petersburg, New Port Richey, Tampa, or anywhere else in the nation and would like to schedule a consultation to discuss PRP therapy, stem cell therapy, or other alternatives to joint surgery with Dr. Lox, please contact Florida Spine and Sports Medicine today.

More:
Tampa Stem Cell Therapy | PRP | Knee | Joint Replacement ...

Read More...

8 Social, Legal, and Ethical Implications of Genetic …

August 4th, 2016 9:36 am

disorder was untreatable as when the disorder was treatable (53 percent would contact a relative about the risk of Huntington disease; 54 percent about the risk of hemophilia A). Since most people at risk for Huntington disease have not chosen testing to see if they have the genetic marker for the disorder,67 geneticists may be overestimating the relative's desire for genetic information and infringing upon the relative's right not to know. They may be causing psychological harm if they provide surprising or unwanted information for which there is no beneficial action the relative can take.

In the legal realm, there is an exception to confidentiality: A physician may in certain instances breach confidentiality in order to protect third parties from harm, for example, when the patient might transmit a contagious disease68 or commit violence against an identifiable individual.69 In a landmark California case, for example, a psychiatrist was found to have a duty to warn the potential victim that his patient planned to kill her.70

The principle of protecting third parties from serious harm might also be used to allow disclosure to an employer when an employee's medical condition could create a risk to the public. In one case, the results of an employee's blood test for alcohol were given to his employer.71 The court held the disclosure was not actionable because the state did not have a statute protecting confidentiality, but the court also noted that public policy would favor disclosure in this instance since the plaintiff was an engineer who controlled a railroad passenger train.

An argument could be made that health care professionals working in the medical genetics field have disclosure obligations similar to those of the physician whose patient suffers from an infectious disease or a psychotherapist with a potentially violent patient. Because of the heritable nature of genetic diseases, a health professional whothrough research, counseling, examination, testing, or treatmentgains knowledge about an individual's genetic status often has information that would be of value not only to the patient, but to his or her spouse or relatives, as well as to insurers, employers, and others. A counterargument could be made, however, that since the health professional is not in a professional relationship with the relative and the patient will not be harming the relative (unlike in the case of violence or infectious diseases), there should be no duty to warn.

The claims of the third parties to information, in breach of the fundamental principle of confidentiality, need to be analyzed, as indicated earlier, by assessing how serious the potential harm is, whether disclosure is the best way to avert the harm, and what the risk of disclosure might be.

The genetic testing of a spouse can give rise to information that is of interest to the other spouse. In the vast majority of situations, the tested individual will share that information with the other spouse. In rare instances, the information will not be disclosed and the health care provider will be faced with the issue of

See the original post here:
8 Social, Legal, and Ethical Implications of Genetic ...

Read More...

Home: Feinberg School of Medicine: Northwestern University

August 4th, 2016 9:36 am

How to manage stress when the world is filled with worry

A little stress can actually be a good thing, motivating us to work hard and get ahead, experts say. But constant stress and worry over the long haul can damage our bodies. "The stress response was made for short-term acute stress, like needing to run away from a bear or a saber tooth tiger," said David Victorson, an associate professor of medical social sciences at the Northwestern University Feinberg School of Medicine and a health psychologist at Northwestern Medicine. "It's been a part of the human process since the beginning. But stressors today can be much more chronic and we're ill equipped to deal with that.

Garfield, an associate professor of pediatrics at the Northwestern University Feinberg School of Medicine, said research on fatherhood is a fairly recent phenomenon, so it's difficult to compare dads of today with fathers in the '60s, for example. But he said change is in the air, as evidenced not only by formal studies, but by cultural phenomena such as the rise of 'dad-vertising,' in which fathers are portrayed as capable, hands-on parents, rather than workaholics or bumbling oafs.

Researchers in Illinois have unveiled the third gene linked with Parkinsons, a discovery that comes following the death of legendary boxer Muhammad Ali, who suffered from the neurodegenerative disease for three decades. Scientists findings, published Monday in Nature Genetics, suggest the genetic mutation TMEM230 was present among Parkinsons patients in North America and Asia, and had similar protein trafficking characteristics as the other two genetic mutations linked with Parkinsons, according to a Northwestern University press release. They found TMEM230 produced a protein involved in the packaging of dopamine in neurons, which is significant because Parkinsons is marked by the breakdown of dopamine-producing neurons.

Not getting a good night's sleep can result in a number of problems including poor concentration, weight gain, and a greater likelihood of accidents. For shift workers and individuals who experience chronic sleep deprivation, new research suggests insufficient sleep could also increase the risk of heart disease. In humans, as in all mammals, almost all physiological and behavioral processes, in particular the sleep-wake cycle, follow a circadian rhythm that is regulated by an internal clock located in the brain," said Daniela Grimaldi, M.D., Ph.D., lead author and a research assistant professor at Northwestern University, said in a press release. "When our sleep-wake and feeding cycles are not in tune with the rhythms dictated by our internal clock, circadian misalignment occurs."

Low-income families with children with allergies spend more than twice as much on visits to emergency rooms and hospitals than mid- to high-income families, recent research from Northwestern University found. And about 40 percent of those children surveyed also reported experiencing life-threatening reactions to food, such as trouble breathing and a drop in blood pressure. "The fact that they were able to open up a food pantry for kids who can't afford the special foods for food allergies incredible," said Dr. Ruchi Gupta, an associate professor of pediatrics who led the Northwestern study, which was published in April.

We need a lot more nonsteroidal options, and [crisaborole] looks like it may be an important addition to our armamentarium, says Jonathan Silverberg, a dermatologist at Northwestern University Feinberg School of Medicine. We have limited options for the thing we can safely give patients without worries about their long term use.

Go here to see the original:
Home: Feinberg School of Medicine: Northwestern University

Read More...

DPH Disease Information: Diabetes Info – Delaware

August 4th, 2016 9:36 am

The Delaware Diabetes and Heart Disease Prevention and Control Program (DHDPCP) goal is to decrease the states emotional, physical, and financial burden from diabetes and heart disease by preventing the diseases and reducing their complications. Our program supports community clinical linkages, health systems interventions, environmental approaches, and epidemiology and surveillance.

The program is funded by a cooperative agreement with the Centers for Disease Control and Prevention (CDC), with additional support from the Delaware Health Fund. The program collects and publicizes current, accurate information about diabetes and heart disease, develops approaches for reducing the impact of the diseases, promotes healthy lifestyle habits for prevention and control, and coordinates efforts of public and private health organizations.

Please note: Some of the files available on this page are in Adobe PDF format which requires Adobe Acrobat Reader. A free copy of Adobe Acrobat Reader can be downloaded directly from Adobe . If you are using an assistive technology unable to read Adobe PDF, please either view the corresponding text only version (if available) or visit Adobe's Accessibility Tools page.

Continued here:
DPH Disease Information: Diabetes Info - Delaware

Read More...

Philadelphia Pennsylvania Office of the American Diabetes …

August 4th, 2016 9:36 am

103

Share:

Pennsylvanians and Delawareans are increasingly feeling the effects of diabetes as thousands of people suffer from the disease, and many others may have diabetes and not know it!

It is estimated that one out of every three children born after 2000 in the United States will be directly affected by diabetes.

That is why the American Diabetes Association's Philadelphia office is so committed to educating the public about how to stop diabetes and support those living with the disease.

We are here to help.

The Philadelphia office serves Eastern Pennsylvania and Delaware.

Additional Events

The American Diabetes Association's Eastern Pennsylvania and Delaware office serves the community with a variety of programs, workshops and awareness campaigns for people living with diabetes, their friends and family. Learn about our available programs.

The following Eastern Pennsylvania and Delaware businesses and organizations have been designated Health Champions from the American Diabetes Association. This designation recognizes organizations that inspire and encourage organizational well-being and is part of the Association's Wellness Lives Here initiative. Learn more.

Christiana Care Health System Delaware Division of Public Health Drexel University Einstein Medical System Health Partners Plans Independence Blue Cross Jefferson Health Navient Novo Nordisk Inc. Nutrisystem Quest Diagnostics The Children's Hospital of Philadelphia University of Pennsylvania Health System YMCA of Greater Brandywine

If you would like a representative from the American Diabetes Association to speak at your event or if you would like materials to distribute at a health fair or expo, please contact 610-828-5003 or bala_office@diabetes.org.

We welcome your help.

Your involvement as an American Diabetes Association volunteer whether on a local or national level will help us expand our community outreach and impact, inspire healthy living, intensify our advocacy efforts, raise critical dollars to fund our mission, and uphold our reputation as the moving force and trusted leader in the diabetes community.

Find volunteer opportunities in our area through the Volunteer Center.

Read the original:
Philadelphia Pennsylvania Office of the American Diabetes ...

Read More...

7. Stem Cells and Diabetes [Stem Cell Information]

August 4th, 2016 9:36 am

Diabetes exacts its toll on many Americans, young and old. For years, researchers have painstakingly dissected this complicated disease caused by the destruction of insulin producing islet cells of the pancreas. Despite progress in understanding the underlying disease mechanisms for diabetes, there is still a paucity of effective therapies. For years investigators have been making slow, but steady, progress on experimental strategies for pancreatic transplantation and islet cell replacement. Now, researchers have turned their attention to adult stem cells that appear to be precursors to islet cells and embryonic stem cells that produce insulin.

For decades, diabetes researchers have been searching for ways to replace the insulin-producing cells of the pancreas that are destroyed by a patient's own immune system. Now it appears that this may be possible. Each year, diabetes affects more people and causes more deaths than breast cancer and AIDS combined. Diabetes is the seventh leading cause of death in the United States today, with nearly 200,000 deaths reported each year. The American Diabetes Association estimates that nearly 16 million people, or 5.9 percent of the United States population, currently have diabetes.

Diabetes is actually a group of diseases characterized by abnormally high levels of the sugar glucose in the bloodstream. This excess glucose is responsible for most of the complications of diabetes, which include blindness, kidney failure, heart disease, stroke, neuropathy, and amputations. Type 1 diabetes, also known as juvenile-onset diabetes, typically affects children and young adults. Diabetes develops when the body's immune system sees its own cells as foreign and attacks and destroys them. As a result, the islet cells of the pancreas, which normally produce insulin, are destroyed. In the absence of insulin, glucose cannot enter the cell and glucose accumulates in the blood. Type 2 diabetes, also called adult-onset diabetes, tends to affect older, sedentary, and overweight individuals with a family history of diabetes. Type 2 diabetes occurs when the body cannot use insulin effectively. This is called insulin resistance and the result is the same as with type 1 diabetesa build up of glucose in the blood.

There is currently no cure for diabetes. People with type 1 diabetes must take insulin several times a day and test their blood glucose concentration three to four times a day throughout their entire lives. Frequent monitoring is important because patients who keep their blood glucose concentrations as close to normal as possible can significantly reduce many of the complications of diabetes, such as retinopathy (a disease of the small blood vessels of the eye which can lead to blindness) and heart disease, that tend to develop over time. People with type 2 diabetes can often control their blood glucose concentrations through a combination of diet, exercise, and oral medication. Type 2 diabetes often progresses to the point where only insulin therapy will control blood glucose concentrations.

Each year, approximately 1,300 people with type 1 diabetes receive whole-organ pancreas transplants. After a year, 83 percent of these patients, on average, have no symptoms of diabetes and do not have to take insulin to maintain normal glucose concentrations in the blood. However, the demand for transplantable pancreases outweighs their availability. To prevent the body from rejecting the transplanted pancreas, patients must take powerful drugs that suppress the immune system for their entire lives, a regimen that makes them susceptible to a host of other diseases. Many hospitals will not perform a pancreas transplant unless the patient also needs a kidney transplant. That is because the risk of infection due to immunosuppressant therapy can be a greater health threat than the diabetes itself. But if a patient is also receiving a new kidney and will require immunosuppressant drugs anyway, many hospitals will perform the pancreas transplant.

Over the past several years, doctors have attempted to cure diabetes by injecting patients with pancreatic islet cellsthe cells of the pancreas that secrete insulin and other hormones. However, the requirement for steroid immunosuppressant therapy to prevent rejection of the cells increases the metabolic demand on insulin-producing cells and eventually they may exhaust their capacity to produce insulin. The deleterious effect of steroids is greater for islet cell transplants than for whole-organ transplants. As a result, less than 8 percent of islet cell transplants performed before last year had been successful.

More recently, James Shapiro and his colleagues in Edmonton, Alberta, Canada, have developed an experimental protocol for transplanting islet cells that involves using a much larger amount of islet cells and a different type of immunosuppressant therapy. In a recent study, they report that [17], seven of seven patients who received islet cell transplants no longer needed to take insulin, and their blood glucose concentrations were normal a year after surgery. The success of the Edmonton protocol is now being tested at 10 centers around the world.

If the success of the Edmonton protocol can be duplicated, many hurdles still remain in using this approach on a wide scale to treat diabetes. First, donor tissue is not readily available. Islet cells used in transplants are obtained from cadavers, and the procedure requires at least two cadavers per transplant. The islet cells must be immunologically compatible, and the tissue must be freshly obtainedwithin eight hours of death. Because of the shortage of organ donors, these requirements are difficult to meet and the waiting list is expected to far exceed available tissue, especially if the procedure becomes widely accepted and available. Further, islet cell transplant recipients face a lifetime of immunosuppressant therapy, which makes them susceptible to other serious infections and diseases.

Before discussing cell-based therapies for diabetes, it is important to understand how the pancreas develops. In mammals, the pancreas contains three classes of cell types: the ductal cells, the acinar cells, and the endocrine cells. The endocrine cells produce the hormones glucagon, somatostatin, pancreatic polypeptide (PP), and insulin, which are secreted into the blood stream and help the body regulate sugar metabolism. The acinar cells are part of the exocrine system, which manufactures digestive enzymes, and ductal cells from the pancreatic ducts, which connect the acinar cells to digestive organs.

In humans, the pancreas develops as an outgrowth of the duodenum, a part of the small intestine. The cells of both the exocrine systemthe acinar cellsand of the endocrine systemthe islet cellsseem to originate from the ductal cells during development. During development these endocrine cells emerge from the pancreatic ducts and form aggregates that eventually form what is known as Islets of Langerhans. In humans, there are four types of islet cells: the insulin-producing beta cells; the alpha cells, which produce glucagon; the delta cells, which secrete somatostatin; and the PP-cells, which produce pancreatic polypeptide. The hormones released from each type of islet cell have a role in regulating hormones released from other islet cells. In the human pancreas, 65 to 90 percent of islet cells are beta cells, 15 to 20 percent are alpha-cells, 3 to 10 percent are delta cells, and one percent is PP cells. Acinar cells form small lobules contiguous with the ducts (see Figure 7.1. Insulin Production in the Human Pancreas). The resulting pancreas is a combination of a lobulated, branched acinar gland that forms the exocrine pancreas, and, embedded in the acinar gland, the Islets of Langerhans, which constitute the endocrine pancreas.

Figure 7.1. Insulin Production in the Human Pancreas. The pancreas is located in the abdomen, adjacent to the duodenum (the first portion of the small intestine). A cross-section of the pancreas shows the islet of Langerhans which is the functional unit of the endocrine pancreas. Encircled is the beta cell that synthesizes and secretes insulin. Beta cells are located adjacent to blood vessels and can easily respond to changes in blood glucose concentration by adjusting insulin production. Insulin facilitates uptake of glucose, the main fuel source, into cells of tissues such as muscle.

( 2001 Terese Winslow, Lydia Kibiuk)

During fetal development, new endocrine cells appear to arise from progenitor cells in the pancreatic ducts. Many researchers maintain that some sort of islet stem cell can be found intermingled with ductal cells during fetal development and that these stem cells give rise to new endocrine cells as the fetus develops. Ductal cells can be distinguished from endocrine cells by their structure and by the genes they express. For example, ductal cells typically express a gene known as cytokeratin-9 (CK-9), which encodes a structural protein. Beta islet cells, on the other hand, express a gene called PDX-1, which encodes a protein that initiates transcription from the insulin gene. These genes, called cell markers, are useful in identifying particular cell types.

Following birth and into adulthood, the source of new islet cells is not clear, and some controversy exists over whether adult stem cells exist in the pancreas. Some researchers believe that islet stem cell-like cells can be found in the pancreatic ducts and even in the islets themselves. Others maintain that the ductal cells can differentiate into islet precursor cells, while others hold that new islet cells arise from stem cells in the blood. Researchers are using several approaches for isolating and cultivating stem cells or islet precursor cells from fetal and adult pancreatic tissue. In addition, several new promising studies indicate that insulin-producing cells can be cultivated from embryonic stem cell lines.

In developing a potential therapy for patients with diabetes, researchers hope to develop a system that meets several criteria. Ideally, stem cells should be able to multiply in culture and reproduce themselves exactly. That is, the cells should be self-renewing. Stem cells should also be able to differentiate in vivo to produce the desired kind of cell. For diabetes therapy, it is not clear whether it will be desirable to produce only beta cellsthe islet cells that manufacture insulinor whether other types of pancreatic islet cells are also necessary. Studies by Bernat Soria and colleagues, for example, indicate that isolated beta cellsthose cultured in the absence of the other types of islet cellsare less responsive to changes in glucose concentration than intact islet clusters made up of all islet cell types. Islet cell clusters typically respond to higher-than-normal concentrations of glucose by releasing insulin in two phases: a quick release of high concentrations of insulin and a slower release of lower concentrations of insulin. In this manner the beta cells can fine-tune their response to glucose. Extremely high concentrations of glucose may require that more insulin be released quickly, while intermediate concentrations of glucose can be handled by a balance of quickly and slowly released insulin.

Isolated beta cells, as well as islet clusters with lower-than-normal amounts of non-beta cells, do not release insulin in this biphasic manner. Instead insulin is released in an all-or-nothing manner, with no fine-tuning for intermediate concentrations of glucose in the blood [5, 18]. Therefore, many researchers believe that it will be preferable to develop a system in which stem or precursor cell types can be cultured to produce all the cells of the islet cluster in order to generate a population of cells that will be able to coordinate the release of the appropriate amount of insulin to the physiologically relevant concentrations of glucose in the blood.

Several groups of researchers are investigating the use of fetal tissue as a potential source of islet progenitor cells. For example, using mice, researchers have compared the insulin content of implants from several sources of stem cellsfresh human fetal pancreatic tissue, purified human islets, and cultured islet tissue [2]. They found that insulin content was initially higher in the fresh tissue and purified islets. However, with time, insulin concentration decreased in the whole tissue grafts, while it remained the same in the purified islet grafts. When cultured islets were implanted, however, their insulin content increased over the course of three months. The researchers concluded that precursor cells within the cultured islets were able to proliferate (continue to replicate) and differentiate (specialize) into functioning islet tissue, but that the purified islet cells (already differentiated) could not further proliferate when grafted. Importantly, the researchers found, however, that it was also difficult to expand cultures of fetal islet progenitor cells in culture [7].

Many researchers have focused on culturing islet cells from human adult cadavers for use in developing transplantable material. Although differentiated beta cells are difficult to proliferate and culture, some researchers have had success in engineering such cells to do this. For example, Fred Levine and his colleagues at the University of California, San Diego, have engineered islet cells isolated from human cadavers by adding to the cells' DNA special genes that stimulate cell proliferation. However, because once such cell lines that can proliferate in culture are established, they no longer produce insulin. The cell lines are further engineered to express the beta islet cell gene, PDX-1, which stimulates the expression of the insulin gene. Such cell lines have been shown to propagate in culture and can be induced to differentiate to cells, which produce insulin. When transplanted into immune-deficient mice, the cells secrete insulin in response to glucose. The researchers are currently investigating whether these cells will reverse diabetes in an experimental diabetes model in mice [6, 8].

These investigators report that these cells do not produce as much insulin as normal islets, but it is within an order of magnitude. The major problem in dealing with these cells is maintaining the delicate balance between growth and differentiation. Cells that proliferate well do not produce insulin efficiently, and those that do produce insulin do not proliferate well. According to the researchers, the major issue is developing the technology to be able to grow large numbers of these cells that will reproducibly produce normal amounts of insulin [9].

Another promising source of islet progenitor cells lies in the cells that line the pancreatic ducts. Some researchers believe that multipotent (capable of forming cells from more than one germ layer) stem cells are intermingled with mature, differentiated duct cells, while others believe that the duct cells themselves can undergo a differentiation, or a reversal to a less mature type of cell, which can then differentiate into an insulin-producing islet cell.

Susan Bonner-Weir and her colleagues reported last year that when ductal cells isolated from adult human pancreatic tissue were cultured, they could be induced to differentiate into clusters that contained both ductal and endocrine cells. Over the course of three to four weeks in culture, the cells secreted low amounts of insulin when exposed to low concentrations of glucose, and higher amounts of insulin when exposed to higher glucose concentrations. The researchers have determined by immunochemistry and ultrastructural analysis that these clusters contain all of the endocrine cells of the islet [4].

Bonner-Weir and her colleagues are working with primary cell cultures from duct cells and have not established cells lines that can grow indefinitely. However the cells can be expanded. According to the researchers, it might be possible in principle to do a biopsy and remove duct cells from a patient and then proliferate the cells in culture and give the patient back his or her own islets. This would work with patients who have type 1 diabetes and who lack functioning beta cells, but their duct cells remain intact. However, the autoimmune destruction would still be a problem and potentially lead to destruction of these transplanted cells [3]. Type 2 diabetes patients might benefit from the transplantation of cells expanded from their own duct cells since they would not need any immunosuppression. However, many researchers believe that if there is a genetic component to the death of beta cells, then beta cells derived from ductal cells of the same individual would also be susceptible to autoimmune attack.

Some researchers question whether the ductal cells are indeed undergoing a dedifferentiation or whether a subset of stem-like or islet progenitors populate the pancreatic ducts and may be co-cultured along with the ductal cells. If ductal cells die off but islet precursors proliferate, it is possible that the islet precursor cells may overtake the ductal cells in culture and make it appear that the ductal cells are dedifferentiating into stem cells. According to Bonner-Weir, both dedifferentiated ductal cells and islet progenitor cells may occur in pancreatic ducts.

Ammon Peck of the University of Florida, Vijayakumar Ramiya of Ixion Biotechnology in Alachua, FL, and their colleagues [13, 14] have also cultured cells from the pancreatic ducts from both humans and mice. Last year, they reported that pancreatic ductal epithelial cells from adult mice could be cultured to yield islet-like structures similar to the cluster of cells found by Bonner-Weir. Using a host of islet-cell markers they identified cells that produced insulin, glucagon, somatostatin, and pancreatic polypeptide. When the cells were implanted into diabetic mice, the diabetes was reversed.

Joel Habener has also looked for islet-like stem cells from adult pancreatic tissue. He and his colleagues have discovered a population of stem-like cells within both the adult pancreas islets and pancreatic ducts. These cells do not express the marker typical of ductal cells, so they are unlikely to be ductal cells, according to Habener. Instead, they express a marker called nestin, which is typically found in developing neural cells. The nestin-positive cells do not express markers typically found in mature islet cells. However, depending upon the growth factors added, the cells can differentiate into different types of cells, including liver, neural, exocrine pancreas, and endocrine pancreas, judged by the markers they express, and can be maintained in culture for up to eight months [20].

The discovery of methods to isolate and grow human embryonic stem cells in 1998 renewed the hopes of doctors, researchers, and diabetes patients and their families that a cure for type 1 diabetes, and perhaps type 2 diabetes as well, may be within striking distance. In theory, embryonic stem cells could be cultivated and coaxed into developing into the insulin-producing islet cells of the pancreas. With a ready supply of cultured stem cells at hand, the theory is that a line of embryonic stem cells could be grown up as needed for anyone requiring a transplant. The cells could be engineered to avoid immune rejection. Before transplantation, they could be placed into nonimmunogenic material so that they would not be rejected and the patient would avoid the devastating effects of immunosuppressant drugs. There is also some evidence that differentiated cells derived from embryonic stem cells might be less likely to cause immune rejection (see Chapter 10. Assessing Human Stem Cell Safety). Although having a replenishable supply of insulin-producing cells for transplant into humans may be a long way off, researchers have been making remarkable progress in their quest for it. While some researchers have pursued the research on embryonic stem cells, other researchers have focused on insulin-producing precursor cells that occur naturally in adult and fetal tissues.

Since their discovery three years ago, several teams of researchers have been investigating the possibility that human embryonic stem cells could be developed as a therapy for treating diabetes. Recent studies in mice show that embryonic stem cells can be coaxed into differentiating into insulin-producing beta cells, and new reports indicate that this strategy may be possible using human embryonic cells as well.

Last year, researchers in Spain reported using mouse embryonic stem cells that were engineered to allow researchers to select for cells that were differentiating into insulin-producing cells [19]. Bernat Soria and his colleagues at the Universidad Miguel Hernandez in San Juan, Alicante, Spain, added DNA containing part of the insulin gene to embryonic cells from mice. The insulin gene was linked to another gene that rendered the mice resistant to an antibiotic drug. By growing the cells in the presence of an antibiotic, only those cells that were activating the insulin promoter were able to survive. The cells were cloned and then cultured under varying conditions. Cells cultured in the presence of low concentrations of glucose differentiated and were able to respond to changes in glucose concentration by increasing insulin secretion nearly sevenfold. The researchers then implanted the cells into the spleens of diabetic mice and found that symptoms of diabetes were reversed.

Manfred Ruediger of Cardion, Inc., in Erkrath, Germany, is using the approach developed by Soria and his colleagues to develop insulin-producing human cells derived from embryonic stem cells. By using this method, the non-insulin-producing cells will be killed off and only insulin-producing cells should survive. This is important in ensuring that undifferentiated cells are not implanted that could give rise to tumors [15]. However, some researchers believe that it will be important to engineer systems in which all the components of a functioning pancreatic islet are allowed to develop.

Recently Ron McKay and his colleagues described a series of experiments in which they induced mouse embryonic cells to differentiate into insulin-secreting structures that resembled pancreatic islets [10]. McKay and his colleagues started with embryonic stem cells and let them form embryoid bodiesan aggregate of cells containing all three embryonic germ layers. They then selected a population of cells from the embryoid bodies that expressed the neural marker nestin (see Appendix B. Mouse Embryonic Stem Cells). Using a sophisticated five-stage culturing technique, the researchers were able to induce the cells to form islet-like clusters that resembled those found in native pancreatic islets. The cells responded to normal glucose concentrations by secreting insulin, although insulin amounts were lower than those secreted by normal islet cells (see Figure 7.2. Development of Insulin-Secreting Pancreatic-Like Cells From Mouse Embryonic Stem Cells). When the cells were injected into diabetic mice, they survived, although they did not reverse the symptoms of diabetes.

Figure 7.2. Development of Insulin-Secreting Pancreatic-Like Cells From Mouse Embryonic Stem Cells. Mouse embryonic stem cells were derived from the inner cell mass of the early embryo (blastocyst) and cultured under specific conditions. The embryonic stem cells (in blue) were then expanded and differentiated. Cells with markers consistent with islet cells were selected for further differentiation and characterization. When these cells (in purple) were grown in culture, they spontaneously formed three-dimentional clusters similar in structure to normal pancreatic islets. The cells produced and secreted insulin. As depicted in the chart, the pancreatic islet-like cells showed an increase in release of insulin as the glucose concentration of the culture media was increased. When the pancreatic islet-like cells were implanted in the shoulder of diabetic mice, the cells became vascularized, synthesized insulin, and maintained physical characteristics similar to pancreatic islets.

( 2001 Terese Winslow, Caitlin Duckwall)

According to McKay, this system is unique in that the embryonic cells form a functioning pancreatic islet, complete with all the major cell types. The cells assemble into islet-like structures that contain another layer, which contains neurons and is similar to intact islets from the pancreas [11]. Several research groups are trying to apply McKay's results with mice to induce human embryonic stem cells to differentiate into insulin-producing islets.

Recent research has also provided more evidence that human embryonic cells can develop into cells that can and do produce insulin. Last year, Melton, Nissim Benvinisty of the Hebrew University in Jerusalem, and Josef Itskovitz-Eldor of the Technion in Haifa, Israel, reported that human embryonic stem cells could be manipulated in culture to express the PDX-1 gene, a gene that controls insulin transcription [16]. In these experiments, researchers cultured human embryonic stem cells and allowed them to spontaneously form embryoid bodies (clumps of embryonic stem cells composed of many types of cells from all three germ layers). The embryoid bodies were then treated with various growth factors, including nerve growth factor. The researchers found that both untreated embryoid bodies and those treated with nerve growth factor expressed PDX-1. Embryonic stem cells prior to formation of the aggregated embryoid bodies did not express PDX-1. Because expression of the PDX-1 gene is associated with the formation of beta islet cells, these results suggest that beta islet cells may be one of the cell types that spontaneously differentiate in the embryoid bodies. The researchers now think that nerve growth factor may be one of the key signals for inducing the differentiation of beta islet cells and can be exploited to direct differentiation in the laboratory. Complementing these findings is work done by Jon Odorico of the University of Wisconsin in Madison using human embryonic cells of the same source. In preliminary findings, he has shown that human embryonic stem cells can differentiate and express the insulin gene [12].

More recently, Itskovitz-Eldor and his Technion colleagues further characterized insulin-producing cells in embryoid bodies [1]. The researchers found that embryonic stem cells that were allowed to spontaneously form embryoid bodies contained a significant percentage of cells that express insulin. Based on the binding of antibodies to the insulin protein, Itskovitz-Eldor estimates that 1 to 3 percent of the cells in embryoid bodies are insulin-producing beta-islet cells. The researchers also found that cells in the embryoid bodies express glut-2 and islet-specific glucokinase, genes important for beta cell function and insulin secretion. Although the researchers did not measure a time-dependent response to glucose, they did find that cells cultured in the presence of glucose secrete insulin into the culture medium. The researchers concluded that embryoid bodies contain a subset of cells that appear to function as beta cells and that the refining of culture conditions may soon yield a viable method for inducing the differentiation of beta cells and, possibly, pancreatic islets.

Taken together, these results indicate that the development of a human embryonic stem cell system that can be coaxed into differentiating into functioning insulin-producing islets may soon be possible.

Ultimately, type 1 diabetes may prove to be especially difficult to cure, because the cells are destroyed when the body's own immune system attacks and destroys them. This autoimmunity must be overcome if researchers hope to use transplanted cells to replace the damaged ones. Many researchers believe that at least initially, immunosuppressive therapy similar to that used in the Edmonton protocol will be beneficial. A potential advantage of embryonic cells is that, in theory, they could be engineered to express the appropriate genes that would allow them to escape or reduce detection by the immune system. Others have suggested that a technology should be developed to encapsulate or embed islet cells derived from islet stem or progenitor cells in a material that would allow small molecules such as insulin to pass through freely, but would not allow interactions between the islet cells and cells of the immune system. Such encapsulated cells could secrete insulin into the blood stream, but remain inaccessible to the immune system.

Before any cell-based therapy to treat diabetes makes it to the clinic, many safety issues must be addressed (see Chapter 10. Assessing Human Stem Cell Safety). A major consideration is whether any precursor or stem-like cells transplanted into the body might revert to a more pluripotent state and induce the formation of tumors. These risks would seemingly be lessened if fully differentiated cells are used in transplantation.

But before any kind of human islet-precursor cells can be used therapeutically, a renewable source of human stem cells must be developed. Although many progenitor cells have been identified in adult tissue, few of these cells can be cultured for multiple generations. Embryonic stem cells show the greatest promise for generating cell lines that will be free of contaminants and that can self renew. However, most researchers agree that until a therapeutically useful source of human islet cells is developed, all avenues of research should be exhaustively investigated, including both adult and embryonic sources of tissue.

Chapter 6|Table of Contents|Chapter 8

Historical content: June 17, 2001

Go here to see the original:
7. Stem Cells and Diabetes [Stem Cell Information]

Read More...

Blood stem cells: the pioneers of stem cell research …

August 4th, 2016 9:36 am

About blood stem cells

Blood stem cells are also known as haematopoietic stem cells. Like other stem cells, they can self-renew, or copy themselves. They also produce the different types of specialized cells found in the blood: both red blood cells and the many kinds of white blood cells needed by the bodys immune system.

The tree of blood: Blood stem cells are at the origin of all blood cell types. Once a blood stem cell divides, its daughter cells take various differentiation routes to produce different types of specialized blood cells.

Specialized blood cells do not live very long, so the body needs to replace them continuously. Blood stem cells do this job. They are found in the bone marrow of long bones such as the femurs (thigh bones), and in the hips or pelvis, the vertebrae (backbones) and the rib cage. They can also be obtained from the umbilical cord blood and the placenta at birth.

Blood stem cells need to make just the right number of each type of blood cell to keep the body healthy. This is a carefully controlled process. When it goes wrong, the result may be a blood disease such as leukaemia or anaemia.

Blood stem cells are already widely used to treat such diseases. A survey in 2008 showed that more than 26,000 patients are treated with blood stem cells in Europe each year. These blood stem cells come from three different sources bone marrow, the bloodstream of an adult or umbilical cord blood.

Scientists are still learning about how blood stem cells develop in the embryo, how they are controlled in the adult body and what goes wrong in certain blood diseases. But they are also using todays understanding of blood stem cells to investigate new ways to treat patients. A bone marrow transplant is only possible if a compatible donor is available. The patient and donor must be very carefully matched to avoid immune rejection of the transplant. Even when a suitable donor can be found, there is still a small risk of rejection. Umbilical cord blood does not need to be matched quite so precisely to the patient, but there are not enough stem cells in an umbilical cord to treat an adult. So we need to find alternatives.

Researchers are investigating ways to produce large numbers of blood stem cells in the laboratory. They are also developing methods for growing specialized blood cells from blood stem cells, for example to produce red blood cells for blood transfusions.

Red blood cells frompluripotent stem cells Red blood cells carry oxygen around the body. Patients who lose a lot of blood need to have it replaced straight away by a blood transfusion. There are not enough blood donors to meet patient needs, so researchers are looking for an alternative solution. Sincepluripotent stem cells have the potential to make any cell type of the body, they could potentially provide an unlimited supply of red blood cells. It is already possible to make small numbers of red blood cells frompluripotent stem cells in the lab. Now the real challenge is to develop techniques for producing the large numbers of red blood cells that are needed for transfusion.

Growing blood stem cells in the lab Red blood cells, like other mature blood cells, are short-lived and specialized for a particular job. To cure disease in the long-term, doctors need to transplant something that can keep producing new blood cells throughout the patients life: blood stem cells. Scientists are searching for ways to grow a limitless supply of blood stem cells. One possibility might be to collect stem cells from the bone marrow then grow and multiply them in the lab. Researchers are also trying to make blood stem cells from embryonic stem cells or induced pluripotent stem (iPS) cells. iPS cells could be made from a patients own skin and then used to produce blood stem cells. This would overcome the problem of immune rejection.

Stem cells for blood - making red blood cells from embryonic stem cells EuroStemCell FAQ page on umbilical cord blood banking The European Group for Blood and Marrow Transplantation UK National Health Service information on bone marrow transplantations Original scientific paper by Till and Mcculloch identifying blood stem cells for the first time

This factsheet was created by Christle Gonneau and reviewed by Lesley Forrester and Cristina Pina.

Lead image of blood cells by Anne Weston/Wellcome Images. Blood stem cell photograph reproduced with permission from Taoudi et al. (2005) "Progressive divergence of definitive haematopoietic stem cells from the endothelial compartment does not depend on contact with the foetal liver", Development 132: 4179- 4191. 'Tree of blood' diagram by Christele Gonneau, with blood cell drawings courtesy of Jonas Larsson, Lund Univeristy, Sweden. All other images courtesy of Joanne Mountford at the University of Glasgow.

View original post here:
Blood stem cells: the pioneers of stem cell research ...

Read More...

318. On His Blindness. John Milton. The Oxford Book of …

August 4th, 2016 9:36 am

Select Search World Factbook Roget's Int'l Thesaurus Bartlett's Quotations Respectfully Quoted Fowler's King's English Strunk's Style Mencken's Language Cambridge History The King James Bible Oxford Shakespeare Gray's Anatomy Farmer's Cookbook Post's Etiquette Brewer's Phrase & Fable Bulfinch's Mythology Frazer's Golden Bough All Verse Anthologies Dickinson, E. Eliot, T.S. Frost, R. Hopkins, G.M. Keats, J. Lawrence, D.H. Masters, E.L. Sandburg, C. Sassoon, S. Whitman, W. Wordsworth, W. Yeats, W.B. All Nonfiction Harvard Classics American Essays Einstein's Relativity Grant, U.S. Roosevelt, T. Wells's History Presidential Inaugurals All Fiction Shelf of Fiction Ghost Stories Short Stories Shaw, G.B. Stein, G. Stevenson, R.L. Wells, H.G. Verse > Anthologies > Arthur Quiller-Couch, ed. > The Oxford Book of English Verse CONTENTSBIBLIOGRAPHIC RECORD Arthur Quiller-Couch, ed. 1919. The Oxford Book of English Verse: 12501900. John Milton.16081674 318.On His Blindness WHEN I consider how my light is spent E're half my days, in this dark world and wide, And that one Talent which is death to hide, Lodg'd with me useless, though my Soul more bent To serve therewith my Maker, and present 5 My true account, least he returning chide, Doth God exact day-labour, light deny'd, I fondly ask; But patience to prevent That murmur, soon replies, God doth not need Either man's work or his own gifts, who best 10 Bear his milde yoak, they serve him best, his State Is Kingly. Thousands at his bidding speed And post o're Land and Ocean without rest: They also serve who only stand and waite.

See the article here:
318. On His Blindness. John Milton. The Oxford Book of ...

Read More...

Arthritis: Causes, Types, Symptoms & Treatment Options …

August 4th, 2016 9:36 am

Arthritis is a condition associated with swelling and inflammation of the joints, which often results in pain and restriction of movement. The most common forms of arthritis are osteoarthritis, which is a breakdown of the cartilage in the joints, and rheumatoid arthritis, which is an inflammation of the tissue lining the joints and in severe cases inflammation of other body tissues. In the joints, sustained inflammation leads to hypertrophy of the synovium and the formation of a "pannus", which spreads over the joint causing erosive destruction of the bone and cartilage. Rheumatoid arthritis occurs when the body's immune system starts attacking it's own organs (joints, bones, internal organs).

Arthritis is a result of a breakdown in cartilage or inflammation.

Cartilage protects joints and enables smooth movement by absorbing shock when pressure is placed on a joint. Without the usual amount of cartilage, the bones rub together and this causes pain, swelling (inflammation), and stiffness.

Joint inflammation can occur for a variety of reasons, including:

Often, the inflammation goes away once the injury has healed, the disease is treated, or once the infection has been cleared. However, with some injuries and diseases, the inflammation does not go away or the cartilage is destroyed and long-term pain and deformity results. When this happens, the disease is called chronic arthritis.

Osteoarthritis is the most common type of arthritis and is more likely to occur with increasing age. It can occur in any of the joints but is most common in the hips, knees or fingers.

Risk factors for osteoarthritis include:

Arthritis can occur in both men and women and in individuals of all ages. Some forms of arthritis also affect children.

As mentioned earlier, the most common forms of arthritis are Osteoarthritis and Rheumatoid arthritis. However, there are numerous forms of arthritis, including:

A person suffering from arthritis may experience any of the following:

A doctor will first note your symptoms and will then look at your medical history in detail to see if arthritis or another musculoskeletal problem is the likely cause of those symptoms.

Your doctor will then perform a thorough physical examination to see if there is any fluid collecting around the joint (an abnormal build up of fluid around a joint is called "joint effusion."). The joint may be tender when gently pressed, and it may also be warm and red (especially if you have infectious arthritis or autoimmune arthritis). You may also find it painful or difficult to rotate the joints in some directions (this is known as "limited range-of-motion").

After this initial physical examination, your doctor may then ask you to undertake a number of different tests, depending on what they suspect to be the cause of your symptoms. Often, you will need to have a blood test and joint x-rays. You may also need to have a test where joint fluid is removed from the joint with a needle; the fluid will then be examined under a microscope to check for infection and for other causes of arthritis, such as crystals, which cause gout.

If arthritis is diagnosed and treated early, you can prevent joint damage. Find out if you have a family history of arthritis and share this information with your doctor, even if you have no joint symptoms. In some autoimmune forms of arthritis, the joints may become deformed if the disease is not treated. Osteoarthritis may be more likely to develop if you over-use your joints. Take care not to overwork a damaged or sore joint. Similarly, avoid excessive repetitive motions. Excess weight also increases the risk for developing osteoarthritis in the knees, and possibly in the hips and hands.

The treatment of arthritis depends on the particular cause of the disease, on the joints that are affected, on the severity of the disorder and on the effect it has on your daily activities. Your age and occupation will also be taken into consideration when your doctor works with you to create a treatment plan.

If possible, treatment will focus on eliminating the underlying cause of the arthritis. However, sometimes the cause is NOT curable, as with osteoarthritis and rheumatoid arthritis. In this case, the aim of treatment will be to reduce pain and discomfort and prevent further disability. Symptoms of osteoarthritis and other long-term types of arthritis can often be improved without medications. Making lifestyle changes without medications is preferable for osteoarthritis and other forms of joint inflammation. If needed, medications should be used in addition to lifestyle changes.

Your doctor will select the most appropriate medication for your form of arthritis.

Most people can take acetaminophen without any problems so long as they do not exceed the recommended dose of 4 grams in 24 hours (taken in 4 divided doses every 4 to 6 hours). It reduces mild pain but does not help with inflammation or swelling. Acetaminophen is available as a combination with other mild pain relief medicines for mild osteoarthritic pain, and with narcotics for severe pain. Acetaminophen with aspirin and or caffeine are over-the-counter medicines. Acetaminophen with codeine, propoxyphene or narcotics are prescription medicines.

Although NSAIDs work well, long-term use of these medicines can cause gastrointestinal problems, such as stomach ulcers and bleeding. In April 2005, the FDA asked manufacturers of NSAIDs to include a warning label on their products that alerts users of an increased risk of cardiovascular events (heart attacks and strokes) and gastrointestinal bleeding.

Taking a combination of NSAIDs or NSAIDs and aspirin together increases the incidence of stomach ulcers or bleeding.

These contain a non steroidal anti-inflammatory drug and a stomach protecting agent, to prevent or treat the gastrointestinal side effects which may be caused by NSAIDs.

COX-2 inhibitors block an inflammation-promoting enzyme called COX-2. This class of drugs was initially believed to work as well as traditional NSAIDs, but with fewer stomach problems. However, numerous reports of heart attacks and strokes have prompted the FDA to re-evaluate the risks and benefits of the COX-2 inhibitors. Rofecoxib (Vioxx) and valdecoxib (Bextra) have been withdrawn from the U.S. market following reports of heart attacks in some patients taking the drugs. The available medicines in this class have been labeled with strong warnings and a recommendation that these be prescribed at the lowest possible dose and for the shortest duration possible.

Corticosteroids have been used to reduce inflammation in rheumatoid arthritis for more than 40 years but it is not known whether they can slow down the progression of disease. It can be used in conjunction with other rheumatoid arthritis medicine.

Potential long-term side effects of corticosteroids limit the use of oral corticosteroids to short courses and low doses where possible. Side effects may include bruising, psychosis, cataracts, weight gain, susceptibility to infections and diabetes, high blood pressure and thinning of the bones (osteoporosis). A number of medications can be administered with steroids to minimize the risk of osteoporosis.

Intra-articular steroid injections can effectively relieve pain, reduce inflammation, increase mobility and reduce deformity in one or a few joints. If repeated injections are required then the dose of DMARDs should be increased.

Corticosteroids suppress the immune system and also reduce pain and inflammation. They are commonly used in severe cases of osteoarthritis and they can be given orally or by injection. Steroid injections are given directly into the joint (intra-articular). Steroids are used to treat autoimmune forms of arthritis but they should be avoided if you have infectious arthritis. Steroids have multiple side effects, including upset stomach and gastrointestinal bleeding, high blood pressure, thinning of bones, cataracts, and increased infections. The risks are most pronounced when steroids are taken for long periods of time or at high doses. Close supervision by a physician is essential.

DMARDs are the most effective agents available for controlling rheumatoid arthritis, but they all have a slow onset of action. Mechanisms of action for most of these agents are not known and they all are different but they all appear to slow or stop the changes in the joints. They can alter laboratory characteristics of disease activity and delay the progression of bone damage.

Patients taking DMARDs generally show some response within 8 to 10 weeks. However, this is variable depending on the patient and drug. Dose of DMARDs is titrated up as far as side effects allow. An additional DMARD is added when the maximum dose is reached, or the initial DMARD is stopped and switched to another.

Most DMARDs require monitoring (such as full blood count, liver function test, urea and electrolyte level test) to ensure drug safety, as the majority can cause bone marrow toxicity and some can cause liver toxicity as well. Regular blood or urine tests should also be done to determine how well medications are working.

Methotrexate is probably the most commonly used DMARD. It is effective in reducing signs and symptoms of rheumatoid arthritis and slows down damage to the joint. Results can be seen in 6 to 8 weeks. Other DMARDs such as hydroxychloroquine and sulfasalazine can used in conjunction with methotrexate.

Hydroxychloroquine, an antimalarial drug, is effective in the treatment of rheumatoid arthritis. It is usually used in combination with methotrexate and sulfasalazine for added benefits.

Sulfasalazine is also an effective DMARD. It can reduce symptoms and slow down the joint damage.

Leflunomide shows similar effectiveness to methotrexate and can be used in patients who cannot take methotrexate.

Tumor necrosis factor (TNF) inhibitors are a relatively new class of medications used to treat autoimmune disease. They include etanercept, infliximab, adalimumab, tocilizumab, certolizumab and golimumab. TNF Inhibitors are also called "Biologics" biological response modifiers.

Tumor necrosis factor alpha is produced by macrophages and lymphocytes, and acts on many cells in the joints and in other organs and body systems. It is a pro-inflammatory cytokine known to mediate most of the joint damage. In rheumatoid arthritis it is produced by the synovial macrophages and lymphocytes. By inhibiting TNF alpha the inflammation process, which attacks or damages the joint tissue, is halted or slowed.

Methotrexate can be used with TNF inhibitors to increase the effectiveness of therapy.

Gold is also effective in the treatment of rheumatoid arthiritis, particularly when given intramuscularly. It isn't used as often now due to its side effects and slow onset of action. Oral gold preparation is available but is less efficacious compared to the intramuscular preparation.

Abatacept decreases T cell proliferation and inhibits the production of the cytokines tumor necrosis factor (TNF) alpha, interferon-?, and interleukin-2.

Rituximab depletes the B cells, which have several functions in the immune response. Rituximab has reduced signs and symptoms of rheumatoid arthritis, and manages to slow down the joint destruction.

The Interleukin-1 Inhibitor, Anakinra, is a new synthetic protein that blocks the inflammatory protein interleukin-1. Anakinra is used to slow progression of moderate to severe active rheumatoid arthritis in patients who have not responded to one or more of the DMARDs.

Alkylating agents, such as cyclophosphamide, are drugs that suppress the immune system and are sometimes used in people who have failed other therapies. These medications are associated with toxic side effects and usually reserved for severe cases of rheumatoid arthritis.

Many people find that over-the-counter nutraceuticals and vitamins, such as glucosamine and chondroitin sulfate help relieve the symptoms of osteoarthritis. There is some evidence that these supplements are helpful in controlling pain, although they do not appear to grow new cartilage.

Bioflavonoids are found in the rind of green citrus fruits and in rose hips and black currants. They have been used historically in a variety of disease states including rheumatic fever, habitual abortion, poliomyelitis, prevention of bleeding, rheumatoid arthritis, periodontal disease, diabetic retinitis, and others.

Diclofenac topical is a non-steroidal anti-inflammatory drug. Although it is applied topically it is still absorbed systemically and may cause systemic effects such as gastrointestinal side effects.

Trolamine salicylate is a topical salicylate pain reliever, used for minor pain and inflammation. It works by reducing swelling and inflammation in the muscle and joints.

Capsaicin is extracted from chillies (genus Capsicum). Capsaicin topical causes a decrease in a substance (substance P) in the body that causes pain. It is used to relieve minor aches and pains of muscle and joints associated with arthritis, simple backache, strains and sprains.

Hyaluronic acid is normally present in joint fluid, and in osteoarthritis sufferers this gets thin. Hyaluronic acid can be injected into the joint to help protect it. This may relieve pain for up to six months.

Non-drug treatment is also important. It is important to make lifestyle changes. Exercise helps maintain joint and overall mobility. Ask your health care provider to recommend an appropriate home exercise routine. Water exercises, such as swimming, are especially helpful. You also need to balance rest with activity. Non-drug pain relief techniques may help to control pain. Heat and cold treatments, protection of the joints and the use of self-help devices are recommended. Good nutrition and careful weight control are important. Weight loss for overweight individuals will reduce the strain placed on the knee and ankle joints.

Physical therapy can be useful for improving muscle strength and motion at stiff joints. Therapists have many techniques for treating osteoarthritis. If therapy does not make you feel better after 3-6 weeks, then it is likely that it will not work at all.

Splints and braces can sometimes support weakened joints. Some prevent the joint from moving, while others allow some movement. You should use a brace only when your doctor or therapist recommends one. The incorrect use of a brace can cause joint damage, stiffness and pain.

Surgery to replace or repair damaged joints may be needed in severe, debilitating cases.

Surgical options include:

Arthroplasty - total or partial replacement of the deteriorated joint with an artificial joint e.g. knee arthroplasty, hip arthroplasty.

Arthroscopic - surgery to trim torn and damaged cartilage and wash out the joint.

Cartilage Restoration - For some younger patents with arthritis, cartilage restoration is a surgical option to replace the damaged or missing cartilage.

Osteotomy - change in the alignment of a bone to relieve stress on the bone or joint.

Arthrodesis - surgical fusion of bones, usually in the spine.

Recommended for you

Follow this link:
Arthritis: Causes, Types, Symptoms & Treatment Options ...

Read More...

Pet Arthritis: Laser Therapy Staves Off Arthritis of Dogs …

August 4th, 2016 9:36 am

Bill Dougherty's trusty 135-pound German shepherd, Rex, has suffered from a limp and joint pain for the past two years. This man's best friend, 70 in dog years, 10 in people years, needed treatment for his arthritic pain. But rather than opting for traditional pills or surgery, Dougherty tried a new, seemingly magical, laser therapy that the local veterinary clinic, Village Animal Clinic in North Palm Beach, Fla., was offering to arthritic dog and cats.

"Rex was always a very active dog, but he started exhibiting some problems with his shoulders," said Dougherty, who owns three other dogs. "He probably has about two years left, and we didn't want to take out six months of his life for surgery, so we tried this."

Dougherty said that Rex's limp and overall activity and happiness improved almost immediately after the first laser treatment.

"We used to say that Rex was like the old man on the hill," said Dougherty. "He'd point out the distraction and then the younger ones would go after it. But now, he's back and a part of the gang."

Mike Berkenblit, owner of Village Animal Clinic and lead veterinarian on site, performed the laser therapeutic procedure on Rex, and many other animals. Other pet owners have seen similar dramatic improvements in their dogs and cats who underwent the treatment.

The cold laser therapy is a noninvasive procedure that uses light to stimulate cells and increase blood circulation. At the correct laser wavelength, pain signals are reduced and nerve sensitivity decreases. The procedure also releases endorphins, or natural painkillers, but it is not recommended for animals that have cancer because the device can stimulate blood flow to cancer cells.

The procedure is based on the idea that light is absorbed into the cells. The process, known as photo-biotherapy, stimulates protein synthesis and cell metabolism, which improves cell health and functionality.

The therapy can take as little as eight to 10 minutes on a small dog or cat, or about a half hour for bigger dogs with more arthritic areas. And to create the appropriate atmosphere, Berkenblit and his staff work to make the dog as comfortable as possible. The animal reclines in a room, the lights are turned down low and soothing music plays in the background.

"We always say that Rex is going to the spa when he goes to get his laser treatment," said Dougherty. "He used to hate going to the vet, but now he loves it. It's where he can go to relax and listen to Beyonce."

Hey, what dog wouldn't love a little soothing Beyonce to set the mood?

This isn't the first time that Berkenblit has put laser treatment to the test. Eight years ago, Berkenblit tried a laser procedure on his own yellow Lab, Woody, but he was unimpressed with the results on his beloved dog.

But about a year ago, he learned of new and improved laser procedures and was convinced to try again.

"I was very skeptical about the treatment at first," said Berkenbilt. "But technology has rocketed ahead and evolved. Now, almost immediately after treatment, people call and say that their animal is doing stuff that he hasn't done in years. It's been a lifesaver for some pets."

Dougherty was so impressed by the results in Rex that he looked into buying a laser device for personal use on his dogs. But the $30,000 price tag hit the bank a bit too hard.

But at $250 for six treatments, Dougherty said that he'll continue to pay for Rex's laser treatments to keep him happy and painfree.

Berkenblit said that the treatment does has not shown any adverse effects so far, although a small portion of dogs and cats will not respond as dramatically to the treatment as Rex and others. About 70 percent of the animals show improvement in arthritic pain. Thirty percent do not experience any change.

Other veterinarians have also been convinced by the buzz surrounding the procedure.

"This is important, exciting stuff," said "Good Morning America's" family doctor for pets Marty Becker. "I'm at the world's largest veterinary meeting in Vegas and seminars on rehab and booths of laser companies are packed."

Most dogs begin showing arthritic symptoms at 6 or 7 years old. While some arthritis can be prevented by maintaining an ideal body weight in one's dog or cat, most dogs will experience some sort of arthritic pain as they grow into old age.

"Laser therapy is a very effective modality to speed and direct healing in dogs with painful arthritis, strains and sprains and other injuries or effects of aging," said Dr. Christine Zink, director of the department of molecular and comparative pathobiology at Johns Hopkins School of Medicine. "It has been used in humans for a long time and dogs now can reap the benefits, too."

And it's Berkenblit himself who put that idea to the test. After spending days crawling around his house after throwing out his back, he finally thought to make his way to the clinic, where he used the laser device on his own back. "I walked out that door and I thought, 'That's pretty cool,'" he said.

Berkenbilt said that other nurses and technicians often use the device for their personal aches and pains, too.

Some may still wonder how lasers can ward off arthritis and pain, but several research studies provide evidence about the benefits of laser therapy treatment.

Dr. Bradley Frederick, director of doctors at the International Sports Science Center and founder of American Health Lasers, uses high-powered lasers to treat people, even professional athletes, on a wide range of injuries and inflammatory conditions.

"We have seen increases in the rate of production of energy after treatment," said Frederick. "The laser stimulates cellular activity to cells that it hits. The key is hitting the cell to accelerate oxidation."

In 2002, the Food and Drug Administration approved its first trial on laser treatment for cell damage. The double-blind studies from Baylor College of Medicine improved carpal tunnel disease in patients about 70 percent more than in the control group using traditional physical therapy programs.

Another study, published in August 2000 in the Journal of Rheumatology, found that cold laser therapy reduced pain by 70 percent and increased tip-to-palm flexibility by more than 1 centimeter, when compared with those in the placebo group.

And finally, a July 2007 study from Wellman Center for Photomedicine at Massachusetts General Hospital in Boston showed that low-level laser therapy was highly effective in reducing swelling in patients with knee-joint arthritis.

Frederick, who has treated several L.A. Clippers basketball players, said that patients often come to him for help when they cannot find any other options to help heal their pain. Different wavelengths and power outlets can treat a variety of injuries, from diabetic ulcers to arthritis and acute injuries.

"I've seen patients who have arthritis so bad that it's bone-on-bone with no cartilage whatsoever," said Frederick. "They will convince me to try and treat them, and I tell them they're probably not going to see any improvements, but there are several who are now at the gym, in the garden, or taking care of their grandkids."

Frederick said the dramatic results, even now, can still sometimes surprise him but warns there are a lot of misconceptions.

"It's a Wild West out there with laser technology," said Frederick. "You're going to see a lot of this used in the future. ...There is an efficacy in this device that just needs a proper amount of energy and delivery system. And we've seen some pretty phenomenal results."

Go here to read the rest:
Pet Arthritis: Laser Therapy Staves Off Arthritis of Dogs ...

Read More...

Stem Cell Therapy or Knee Replacement Adelaide

August 4th, 2016 9:36 am

What is stem cell therapy?

Stem cell therapy is the use of your bodys own stem cells to repair a joint. The procedure involves four main steps.

After the procedure it is recommended that you have a follow up appointment with Norwood Day Surgery 3 days, 2 weeks, 2 months and 6 months after your procedure. Your doctor will discuss your progress with you and may utilise standardised pain tests such as WOMAC or HOOS depending on the joint where you received treatment.

In a study at our practice 100osteoarthritis patients were treated with stem cell therapy and assessed each month for 6 months. It was reported that over 75% of patients treated, showed a significant improvement between 50 100% in pain and mobility of the joint.

Approximately 15% of patients treated were non-responders and had an improvement of less than 20% after 3 months.

The repair process takes time with the improvement at its maximum level by 6 months. Whether young or old the improvement after receiving stem cell therapy was the same. It is too early to determine the lifespan of the treatment as this treatment has only been available since 2009, with only 10% of our patients needing a second treatment.

Many thousands of patients with osteoarthritis have now been treated with stem cell therapy. We know that it is a safe procedure if done carefully.

Minor adverse events have been observed on the day of the procedure in a small percentage of patients and include: slight fever, rash, euphoria followed by a transient depression and cramps in the toes and feet.

Common liposuction short-term side effects may include: abdominal pain, bruising (which may last up to two weeks), and leakage of anaesthetic fluid for 24 hours. One case of bleeding has occurred from a sensitivity to intravenous injection of stromal vascular fraction.

The rest is here:
Stem Cell Therapy or Knee Replacement Adelaide

Read More...

Patent Docs: Personalized Medicine

August 4th, 2016 9:36 am

By Kevin E. Noonan --

The promise of an era of "personalized medicine" has been pursued for a generation, being one of the rationales for and purported benefits of the Human Genome Project. It has become such a sought-for goal that it has been used to drive policy: it is something that health care reform is banking on (literally), since by making medicine more individualized, success rates and fewer failed therapies are envisioned. It crept into the gene patenting debate, with Judge Bryson in his dissent crediting the ACLU's claim that gene patents will inhibit development of personalized medicine (they won't). But as others have noted (for example, Nicholas Wade, "A dissenting voice as the genome is sifted to fight disease," The New York Times, September 15, 2008), a promise is all it remains: achieving a personalized medicine future has proven (so far) to be much more daunting than its proponents believed (or told the rest of us to believe).

The results of a cancer study in the New England Journal of Medicine last week may have shed some light on what this has been so. The report, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing," a team of physicians and scientists from the UK and Harvard revealed that the genetics of human tumors is much more complicated than previously thought (Gerlinger et al., 2012, N. Engl. J. Med. 366: 883-92). These researchers obtained multiple biopsy samples from different regions of the same tumor (primary and metastatic) and performed multilocus genomic sequencing. The tumors were all a particular subtype of primary renal cell carcinoma, clear cell carcinoma (CCC) from patients that had been treated with everolimus (Zortress, an mTOR inhibitor) therapy before and after nephrectomy. Whole exome multiregion spatial DNA sequencing (see below) was performed on extracted tissue from fresh frozen samples as well as SNP analysis and mRNA expression profiling using gene arrays.

Exome Sequencing - Part I:

Exome Sequencing - Part 2

The results showed a significant amount of genetic heterogeneity that could be related to chemotherapeutic drug resistance and differential metastatic potential. In one CCC patient, nine regions of the primary tumor and three regions of metastatic tumors (as well as the germline DNA sequences) were assayed. A 2 bp deletion in the von Hippel-Lindau (VHL) tumor suppressor gene was found, a genetic characteristic of CCC. These analyses revealed 101 nonsynonymous point mutations and 32 instances of insertion or deletion (indels), with the assays showing a low false negative rate of detection. From a total of 128 mutations detected in the various samples, 40 were "ubiquitous" mutations (found in all samples), 59 were shared by "several but not all" regions, and 29 were unique to a particular region (called "private mutations"). Of the "shared" mutations, 31 were shared by most of the primary tumor samples, and 28 shared by most of the metastatic tumor samples. "The detection of private mutations suggested an ongoing regional clonal evolution," the authors concluded from this data.

From these results, the workers constructed a phylogenetic tree that revealed "branching rather than linear" tumor evolution. Deeper analysis showed that, in some regions, the primary tumor shared more mutation with the metastases than with other areas of the primary tumor, suggesting the existence of two "clonal populations of progenitor cells in this region." The study also compared these results with results from a "single" tumor biopsy study, which detected 70 somatic mutations (about 55% of the total detected using the multiregional approach). These figures were put into context by noting that only 31-34% of all mutations detected using the multiregional sampling/sequencing were detected in all regions. Finally, any major effect of the everolimus treatment on these results was discounted by finding that 67/71 mutations found after treatment were present in the tumor samples pretreatment, and that 64/66 chest wall metastasis mutations were found in post-treatment metastatic tumors. These results indicated to the researchers that "the two main branches of the phylogenetic tree were present before drug treatment" and that "60% of the mutations in pretreatment samples of the primary tumor and chest-wall metastases were not shared by both biopsy samples," i.e., evidence of clonal evolution that would have required reversion of somatic mutations during treatment (not very likely).

A conventional measure of tumor heterogeneity, ploidy analysis (i.e., how many chromosomes and chromosome fragments were present in the tumor cells) was also performed. While the primary tumor was predominantly diploid (i.e., facially "normal") there were two regions in the metastatic tumors that were subtetraploid (i.e., a few fewer than twice the [n]o limited by sample quality issues showed ubiquitous "allelic imbalance" on the short arm of the 3rd chromosome (3p) characterized by loss of heterozygosity at multiple allelic loci), including VHL and histone H3K36 methyltransferase SETD2. Even here, "tumor regions shared identical allelic-imbalance profiles, and heterogeneity of allelic imbalance within metastases, which is probably driven by aneuploidy, indicates that chromosomal aberrations contribute to genetic intratumor heterogeneity."

The study also compared the mutational status of genes known to be mutated in CCC, including VHL, SETD2, KDM5C, and mTOR. Only the VHL gene was ubiquitously mutated in all regions sampled, contrasted in the study by the mutational nature of SETD2: the metastases all showed a missense mutation while one primary region had a splice site mutation and the others showed a 2 bp frameshift deletion (which was also present in the region with the frameshift mutation). Convergent evolution was detected with regard to SETD2 histone methylation using functional assays; such convergent genetic evolution in tumor cells was also detected for the X chromosome-encoded histone methyltransferase KDM5C.

Another gene, mTOR, showed a missense mutation in the portion of the gene encoding a kinase domain; this mutation was found in all but one of the primary tumor regions tested. The researchers also reported that a currently used test for CCC, a 110-gene signature that assesses patient prognosis, displayed anomalous results: the metastases and one primary tumor sample showed the "good" prognostic pattern while all the other primary sites showed the "poor" prognostic pattern. The authors caution that "prognostic gene-expression signatures may not correctly predict outcomes if they are assessed from a single region of a heterogeneous tumor."

The workers performed similar analyses on three other patients. In one, patient 2, the researchers found 119 somatic mutations what also showed a branching pattern of clonal genetic evolution in this patient's tumor. Here, ~31-37 of the mutations were found ubiquitously (the lower number was obtained when the metastases were included). While no ploidy imbalance was detected in these tumor samples, allelic imbalance was found ubiquitously in all tested regions for 3p and on the long arm of chromosome 10 (10q). In addition to some of the 3p mutations found in patent 1's tumor, mutations were found for genes residing on 10q, including PTEN. Convergent evolution was also observed for the PTEN gene. Similar results were obtained and briefly noted for tumor samples obtained from patients 3 and 4 (patient 4's tumors showed allelic imbalance on chromosomes 5 (5q) and6 (6q)). However, "[t]hese early ubiquitous events were outnumbered by non-ubiquitous aberrations, indicating that the majority of chromosomal events occurred after tumors diverged, providing further evidence of branching evolution." Patient 4 also showed tumor heterogeneity in genes like SETD2 that had been detected in other tumor samples.

The authors summarized their results by noting that they had detected genetic heterogeneity in each tumor assayed, showing "spatial separated heterogeneous somatic mutations and chromosomal imbalances." These genetic lesions lead to phenotypic heterogeneity, with 63-69% of the mutations not detected in every tumor region sampled. Their detection of "ubiquitous alterations on the trunk of the tumor phylogenetic tree . . . may account for the benefits of cytoreductive nephrectomy" because it reduces the "reservoir" of primary tumors cells capable of genetic instability and failure to respond to more "conventional" regions of the tumor. Finally, the authors state that:

Genomics analyses from single tumor-biopsy specimens may underestimate the mutational burden of heterogeneous tumors. Intratumor heterogeneity may explain the difficulties encountered in the validation of oncology biomarkers owing to sampling bias, contribute to Darwinian selection of preexisting drug-resistant clones, and predict therapeutic resistance. Reconstructing tumor clonal architectures and the identification of common mutations located in the trunk of the phylogenetic tree may contribute to more robust biomarkers and therapeutic approaches.

These results illustrate a few things. First, the gene patenting debate per se is anachronistic and ten if not thirty years out of date. The complexity revealed by this study provides one reason why approaches tried thus far for implementing personalized medicine have not worked out as well as planned. This complexity suggests that it will take far more time to produce a worthwhile personalized medicine paradigm that fulfills all its unfulfilled promises and that the "gene age" will likely be long past by that time.

This very same complexity reinforces the risk in making any broad pronouncements against the patent-eligibility of "products to nature." With this level of complexity, the number of "false negatives" (and, presumably, false positives) may make it possible to identify diagnostic genetic markers for disease prognosis that can be protected without patents. As noted by the authors, identification of the "trunk" mutations (shared by the largest number of tumor samples) provide the best information on the tumor for treatment, prognosis and otherwise. The negative consequences of changing the incentives from disclosure (protected by patenting) and non-disclosure (protected, inter alia as a trade secret) has been discussed here before; this study points to ways that could be profitable for the company that develops the test at the cost of reaching the goal of personalized medical care. Because the alternative may be no personalized medical care at all, it behooves participants in the policy debate about gene patents, genetic diagnostic testing, and innovation to consider this study to be but the first in a long series demonstrating that, indeed, we are only at the beginning of the road when it comes to developing a robust personalized medicine system.

Images of exome sequencing (above) by SarahKusala, from the Wikipedia Commons (Part I & Part 2) under the Creative Commons Attribution 3.0 Unported license.

More here:
Patent Docs: Personalized Medicine

Read More...

Personalized Medicine SFSU

August 4th, 2016 9:36 am

Join us for Personalized Medicine 9.0: Gene Therapy & Genome Editing This changes everything! Thursday 26 May 2016 8:00 a.m. to 6:00 p.m. An exciting topic every year South San Francisco Conference Center Personalized medicine seeks to use genetic variation to develop new diagnostic tests and treatments and to identify the sub-groups of patients for whom they will work best. This approach can also help determine which groups of patients are more prone to developing some diseases and, ideally, help with the selection of lifestyle changes and/or treatments that can delay onset of disease or reduce its impact. This year, in our ninth annual conference on personalized medicine, we address the promise of technologies like genome editing for gene therapy and drug discovery. The correction of genetic disease has been elusive until very recently, but the process of genome editing through the CRISPR/Cas9 system has revolutionized the field with unprecedented speed, and unparalleled opportunities. CRISPR has also proved to be one of the most powerful tools in basic genetics and biology developed in the last century, and provides new ways to understand cellular function. Using this knowledge, we have the potential to create pharmaceuticals and diagnostic tests with a speed and accuracy never before imagined. We explore the science behind gene therapy and genome editing, the realization of new diagnostic tools and treatments, the ethics of germline gene manipulation, and the implications for the future of the pharmaceutical industry and the human species. For further information or to sponsor this event, email us at dnamed@sfsu.edu Personalized Medicine The Time is Now We are happy to accommodate persons with special access requirements. Please contact Mike Goldman at: goldman@sfsu.edu or 415.338.1549

Read the original post:
Personalized Medicine SFSU

Read More...

Personalized Medicine | Labcyte Inc.

August 4th, 2016 9:36 am

FIMMs Individual Systems Medicine (ISM) approach relies on the Echo Liquid Handler from Labcyte, which uses acoustic energy to enable precise screening of potential therapies in a high-throughput, cost-effective manner.

FEATURED PUBLICATION

Journal of Laboratory Automation (JALA) Special Issue February 2016

Kristin Blom, et al. Department of Medical Sciences, Uppsala University

Although medical cancer treatment has improved during the past decades, it is difficult to choose between several first-line treatments supposed to be equally active in the diagnostic group. It is even more difficult to select a treatment after the standard protocols have failed. Any guidance for selection of the most effective treatment is valuable at these critical stages. We describe the principles and procedures for ex vivo assessment of drug activity in tumor cells from patients as a basis for tailored cancer treatment. Patient tumor cells are assayed for cytotoxicity with a panel of drugs. Acoustic drug dispensing provides great flexibility in the selection of drugs for testing; currently, up to 80 compounds and/or combinations thereof may be tested for each patient. Drug response predictions are obtained by classification using an empirical model based on historical responses for the diagnosis. The laboratory workflow is supported by an integrated system that enables rapid analysis and automatic generation of the clinical referral response.

Test combinations of drugs, antibodies, and siRNA molecules in low volumes to identify impacts to cell functioning or toxicity. Echo liquid handlers reliably transfer samples and reagents from any well to any well to improve assay sensitivity and reproducibility.

Recently identified associations between variants of cancer genes and drug resistance have increased the value for comprehensive drug sensitivity screening in combination with molecular profiling of cancer cells. In cancer research, the information from drug sensitivity screening is often used to improve the precision of therapy offered to patients. This can involve treatment with re-purposed therapeutics, novel therapeutics or combinations of therapeutics. Comparison of drug sensitivity information along with the molecular profile of certain cancer cells can enable the identification of underlying genetic links to drug resistance.

As these programs are scaled up, operational costs to prepare samples and perform screening can become rate limiting, delaying treatment decisions. Researchers have found that miniaturization from the use of acoustic liquid handling instead of traditional methods has increased the overall efficiency of drug sensitivity screening by lowering costs while improving data quality and throughput. Echo Dose-Response software enables direct dilution and normalization of simple or complex concentration curves from a range of sample types. With direct dilution, Echo Liquid Handlers produce dose-response assays without the risk of carryover or contamination common to tip-based serial dilution methods.

View post:
Personalized Medicine | Labcyte Inc.

Read More...

What Is Personalized Cancer Medicine? | Cancer.Net

August 4th, 2016 9:36 am

Personalized medicine is used to learn about a persons genetic makeup and how their tumor grows. Using this data, doctors hope to find prevention, screening, and treatment strategies that may be more effective. They also want to find treatments that cause fewer side effects than the standard options. By performing genetic tests on the cancer cells and on normal cells, doctors may be able to customize treatment to each patients needs.

Creating a personalized cancer screening and treatment plan includes:

Determining the chances that a personwill develop cancer and selecting screening strategies to lower the risk

Matching patients with treatments thatare more likely to be more effective and cause fewer side effects

Predicting the risk of recurrence, whichis the return of cancer

Before personalized medicine, most patients with a specific type and stage of cancer received the same treatment. However, it became clear that some treatments worked better for some patients, than for others. The growth in the field of genetics has led researchers to find genetic differences in people and their tumors. In turn, this explained many of the different responses to treatment. A person with cancer may now still receive a standard treatment plan, such as surgery to remove a tumor. However, the doctor may also be able to recommend some type of personalized cancer treatment. Personalized cancer treatment is now an active part of the treatment plan or as part of a clinical trial. A clinical trial is a research study involving people.

Some examples of personalized medicine strategies for cancer include the following:

Targeted treatments. A targeted treatmenttargets a cancers specific genes and proteins that allow the cancer cells to grow and survive. Researchers are finding new targets each year and creating and testing new drugs for these targets. This is a few, but not all of the cancers where targeted treatments are used.

Breast cancer

Colorectal cancer

Gastrointestinal stromal tumor

Kidney cancer

Lung cancer

Melanoma

Multiple myeloma

Some types of leukemia and lymphoma

Some types of childhood cancers

Of course, treatment with a targeted therapy depends on finding out whether the tumor has the specific target. This is found by testing a sample of the tumor.

Pharmacogenomics. Pharmacogenomicslooks at how a persons genes affect the way the body processes and responds to drugs. These changes influence how effective and safe a drug is for a person. For example, some peoples bodies may process a medicine more quickly than others. This means that the person would require a higher dose of that drug for it to be effective. However, someone elses body may not process a drug as quickly. The drug would then stay in the bloodstream for a longer time and may cause more severe side effects.

How can pharmacogenomics be used for cancer treatments? Here is an example: People with colorectal cancer sometimes have a specific altered gene. These patients may have serious side effects when treated with the drug, irinotecan (Camptosar). This gene makes it harder for the body to break down the drug. In these patients, doctors prescribe lower amounts of the medicine so patients will have fewer side effects.

Despite the promises of personalized cancer treatments, not all types of cancer have personalized treatment options. Some of these are only offered through a clinical trial and are not yet standard treatment options. Genetic testing for patients and tumor samples may be costly and time-consuming. Also, many insurance plans may not cover the costs of these tests. In addition, some personalized treatments, such as targeted treatments, can also be expensive.

Personalized medicine is an evolving approach to cancer treatment. Doctors still dont know all about the genetic changes that occur in a cancer cell. They also dont know how some of these new cancer treatments work. A targeted therapy may stop working and a promising treatment is no longer effective. Talk with your doctor to learn if personalized cancer treatments may be a part of your treatment plan.

To learn more about personalized cancer care, consider asking your doctor the following questions:

What are my treatment options?

What clinical trials are open to me?

Are there tests available that can help guide treatment choices?

Is this treatment considered an example of personalized medicine? If so, how?

What are the benefits of this treatment?

What are the potential side effects ofthis treatment?

What is my chance of recovery?

Financial Considerations

Introduction to Cancer Research

Originally posted here:
What Is Personalized Cancer Medicine? | Cancer.Net

Read More...

Legal Issues – udel.edu

August 4th, 2016 9:36 am

Legal Issues

Common-Law Protection of Genetic Information Privacy

Some protection for genetic information privacy is offered by common law tort remedies. The common law right of privacy prevents public disclosure of private facts. Most courts have, however, found that such a claim requires widespread disclosure to the public, which will not occur in most cases involving the release of personal genetic information. Another restrictive element of the public disclosure tort is that most courts require disclosure to someone without a "legitimate interest" in the information. Some courts consider employers to have such a legitimate interest in much of their worker's medical information.

The tort right of privacy also prevents intentional intrusions upon the private affairs or concerns of an individual. Such intrusions, however, must be "highly offensive." Miller v. Motorola illustrates the weakness of the intrusion tort action for protecting genetic information privacy. In this case, an employer disclosed sensitive medical information to the plaintiff's co-workers. The Illinois court found no "intrusion" on the plaintiff because she had "voluntarily provided" the information to her employer.

Statutory Protection of Genetic Information Privacy

United States Constitution

The act of genetic testing raises the issue of Fourth Amendment protection from unreasonable bodily intrusions. However, the Fourth Amendment provision against unreasonable searches and seizures is inapplicable to private organizations in the absence of state action. The effects of genetic testing may be attacked under two Fourteenth Amendment doctrines as well. The first is the Fourteenth Amendment's substantive due process protection of the right of privacy. The second is the guarantee of equal protection. Some genetic diseases are primarily confined to certain racial groups, raising the possibility of creating a suspect class. In addition, there may be a question of restrictions on procreative choice resulting from directive counseling. Such counseling could infringe fundamental liberty rights. Finally, the act of genetic testing may be contrary to certain religious beliefs. Mandatory genetic testing programs may violate the First Amendment's guarantee of religious freedom.

When the government collects personal data, a constitutional right to informational privacy applies to the data collected. This right was first identified in Whalen v. Roe, a case that involved medical data. Whalen concerned a New York State plan to collect and store information relating to the prescription of certain drugs that had both legitimate and illegitimate applications. In judging the constitutionality of this state scheme, the Supreme Court found that the United States Constitution included a right of informational privacy that prohibited "disclosure of personal matters" and protected "independence" in decision-making.

To check whether the nondisclosure interest had been violated, the Court examined the data security measures of New York. These measures included storing the prescription forms in a vault until their ultimate destruction; surrounding the room in which these data were received with a wire fence and protecting this area with an alarm system; and promulgating statutory and regulatory measures that prohibited disclosure to the public. The Court found such actions were well designed to ensure that the personal medical data collected by the state government would be kept from the public.

The second Whalen interest, independence in making certain types of important decisions, was implicated by the patient's decision whether to acquire and use needed medicine. Although the government's record-keeping had discouraged some use of the drugs in question, "the decision to prescribe, or to use" remained in the control of the physician and the patient. Therefore, the Court found that New York's data processing scheme did not violate interest of independence in decision making. The Whalen two-branch approach offers a model with potential for the protection of personal genetic information.

Unfortunately, lower courts analyzing governmental attempts to obtain or examine medical information have done so primarily with reference to the first Whalen interest. Indeed, some courts have even viewed Whalen as a decision that sanctions all "legitimate" governmental requests for medical data. The independence of decision making interest identified in Whalen has been almost entirely absent from case law. Thus, although Whalen offers a potentially useful element in the overall structure of a genetic information privacy protection law, it has not led to vigorous protection of medical or genetic information privacy. Finally, in the absence of state legislation, private parties may conduct across-the-board genetic testing without the constitutional implications faced by federally funded programs. Thus, private employers, insurers, and social organizations may test all applicants under existing law.

Americans With Disabilities Act[68]

The Americans With Disabilities Act ("ADA") serves to prevent discrimination against individuals with disabilities in critical areas like employment, housing, public accommodations, education, transportation, health services, and access to public services. If individuals subjected to genetic testing are discriminated against as a result of such testing, they are protected by the ADA because they are "perceived" to be disabled. Thus, even though the genetic disorder may not manifest itself physically to the point of limiting one or more of the major life activities of the individual, any person who is believed to be disabled would be protected by the ADA.

However, as a defense, the ADA permits employers to use techniques like genetic testing to screen individuals to find out if they have disabilities that pose a significant threat to the health and safety of other workers. The ADA can provide some protection against discrimination resulting from genetic testing in employment and other federally funded areas. However, it does not address the use of genetic information in law enforcement, adoption, insurance, or confidentiality and privacy issues.

The Human Genome Privacy Act[72]

The Human Genome Privacy Act ("HGPA") was introduced on September 17, 1990, to Congress by Representative John Conyers, Jr. (D-Mich.). The HGPA attempts to offer protection to genetic information by allowing greater individual control over the use and verification of genetic information.

First, the HGPA permits the individual to inspect any genetic information on himself or herself maintained by a government agency. Second, the HGPA allows an individual to request amendment of any personal genetic information maintained by the agency while granting the agency the right to refuse to amend. These provisions of the HGPA enable an individual to ensure that accurate results are maintained, and they also allow the individual to verify false positives and update his or her genetic database. Third, the HGPA requires all agencies maintaining genetic information to provide written notice of their practices, including the rights of an individual to inspect and amend genetic data. Section 143(a) of the HGPA provides that intentional and unauthorized disclosure, maintenance, or security of genetic information shall be punishable as a misdemeanor and carry a fine of up to $10,000 In addition, the HGPA provides declaratory and injunctive relief to individuals whose rights have been violated.

Requiring individuals to consent to disclosure of their information rather than simply notifying them of such disclosure would provide individuals with greater security and privacy. This provision would restrict the flow of genetic information and enable people to trace the source of leaked genetic data more easily. Disclosure without an individual's authorization is permitted under the HGPA only in medical emergencies, clinical-care circumstances, or adoption situations when "reasonable efforts to locate the individual" have failed, and when required by law.

While well intentioned and timely, the HGPA's effectiveness is doubtful. First, its operative language is vague. How far must one go to prevent misuse, including possible unlawful discrimination by third parties? The civil and criminal penalty provisions in the HGPA do not address this issue. Although the HGPA provides individuals with some autonomy in maintaining their genetic records, the HGPA does not give any guidelines as to when and how individuals may amend their records, or the use of the data before they are altered. The HGPA indicates that the agencies holding genetic data are the sole arbiters of all requests for information. This leaves the agencies with much discretion.

Our conclusion about the issues presented on this web site is presented here.

Back to Home

Read the original:
Legal Issues - udel.edu

Read More...

Psychological Stress and the Human Immune System: A Meta …

August 4th, 2016 9:36 am

Psychol Bull. Author manuscript; available in PMC 2006 Feb 7.

Published in final edited form as:

PMCID: PMC1361287

NIHMSID: NIHMS4008

Suzanne C. Segerstrom, University of Kentucky;

The present report meta-analyzes more than 300 empirical articles describing a relationship between psychological stress and parameters of the immune system in human participants. Acute stressors (lasting minutes) were associated with potentially adaptive upregulation of some parameters of natural immunity and downregulation of some functions of specific immunity. Brief naturalistic stressors (such as exams) tended to suppress cellular immunity while preserving humoral immunity. Chronic stressors were associated with suppression of both cellular and humoral measures. Effects of event sequences varied according to the kind of event (trauma vs. loss). Subjective reports of stress generally did not associate with immune change. In some cases, physical vulnerability as a function of age or disease also increased vulnerability to immune change during stressors.

Since the dawn of time, organisms have been subject to evolutionary pressure from the environment. The ability to respond to environmental threats or stressors such as predation or natural disaster enhanced survival and therefore reproductive capacity, and physiological responses that supported such responses could be selected for. In mammals, these responses include changes that increase the delivery of oxygen and glucose to the heart and the large skeletal muscles. The result is physiological support for adaptive behaviors such as fight or flight. Immune responses to stressful situations may be part of these adaptive responses because, in addition to the risk inherent in the situation (e.g., a predator), fighting and fleeing carries the risk of injury and subsequent entry of infectious agents into the bloodstream or skin. Any wound in the skin is likely to contain pathogens that could multiply and cause infection (Williams & Leaper, 1998). Stress-induced changes in the immune system that could accelerate wound repair and help prevent infections from taking hold would therefore be adaptive and selected along with other physiological changes that increased evolutionary fitness.

Modern humans rarely encounter many of the stimuli that commonly evoked fight-or-flight responses for their ancestors, such as predation or inclement weather without protection. However, human physiological response continues to reflect the demands of earlier environments. Threats that do not require a physical response (e.g., academic exams) may therefore have physical consequences, including changes in the immune system. Indeed, over the past 30 years, more than 300 studies have been done on stress and immunity in humans, and together they have shown that psychological challenges are capable of modifying various features of the immune response. In this article we attempt to consolidate empirical knowledge about psychological stress and the human immune system through meta-analysis. Both the construct of stress and the human immune system are complex, and both could consume book-length reviews. Our review, therefore, focuses on those aspects that are most often represented in the stress and immunity literature and therefore directly relevant to the meta-analysis.

Despite nearly a century of research on various aspects of stress, investigators still find it difficult to achieve consensus on a satisfactory definition of this concept. Most of the studies contributing to this review simply define stress as circumstances that most people would find stressful, that is, stressors. We adopted Elliot and Eisdorfers (1982) taxonomy to characterize these stressors. This taxonomy has the advantage of distinguishing among stressors on two important dimensions: duration and course (e.g., discrete vs. continuous). The taxonomy includes five categories of stressors. Acute time-limited stressors involve laboratory challenges such as public speaking or mental arithmetic. Brief naturalistic stressors, such as academic examinations, involve a person confronting a real-life short-term challenge. In stressful event sequences, a focal event, such as the loss of a spouse or a major natural disaster, gives rise to a series of related challenges. Although affected individuals usually do not know exactly when these challenges will subside, they have a clear sense that at some point in the future they will. Chronic stressors, unlike the other demands we have described, usually pervade a persons life, forcing him or her to restructure his or her identity or social roles. Another feature of chronic stressors is their stabilitythe person either does not know whether or when the challenge will end or can be certain that it will never end. Examples of chronic stressors include suffering a traumatic injury that leads to physical disability, providing care for a spouse with severe dementia, or being a refugee forced out of ones native country by war. Distant stressors are traumatic experiences that occurred in the distant past yet have the potential to continue modifying immune system function because of their long-lasting cognitive and emotional sequelae (Baum, Cohen, & Hall, 1993). Examples of distant stressors include having been sexually assaulted as a child, having witnessed the death of a fellow soldier during combat, and having been a prisoner of war.

In addition to the presence of difficult circumstances, investigators also use life-event interviews and life-event checklists to capture the total number of different stressors encountered over a specified time frame. Depending on the instrument, the focus of these assessments can be either major life events (e.g., getting divorced, going bankrupt) or minor daily hassles (e.g., getting a speeding ticket, having to clean up a mess in the house). With the more sophisticated instruments, judges then code stressor severity according to how the average person in similar biographical circumstances would respond (e.g., S. Cohen et al., 1998; Evans et al., 1995).

A smaller number of studies enrolled large populations of adults who were not experiencing any specific difficulty and examined whether their immune responses varied according to their reports of perceived stress, intrusive thoughts, or both. Other studies have examined stressed populations, in which a larger range of subjective responses may be detected. This work grows out of the view that peoples biological responses to stressful circumstances are heavily dependent on their appraisals of the situation and cognitive and emotional responses to it (Baum et al., 1993; Frankenhauser, 1975; Tomaka, Blascovich, Kibler, & Ernst, 1997).

As many behavioral scientists are unfamiliar with the details of the immune system, we provide a brief overview. For a more complete treatment, the reader is directed to the sources for the information presented here (Benjamini, Coico, & Sunshine, 2000; Janeway & Travers, 1997; Rabin, 1999). Critical characteristics of various immune components and assays are also listed in .

Immune Parameters Reported and Critical Characteristics

There are several useful ways of dividing elements of the immune response. For the purposes of understanding the relationship of psychosocial stressors to the immune system, it is useful to distinguish between natural and specific immunity. Natural immunity is an immune response that is characteristic not only of mammals but also lower order organisms such as sponges. Cells involved in natural immunity do not provide defense against any particular pathogen; rather, they are all-purpose cells that can attack a number of different pathogens1 and do so in a relatively short time frame (minutes to hours) when challenged. The largest group of cells involved in natural immunity is the granulocytes. These cells include the neutrophil and the macrophage, phagocytic cells that, as their name implies, eat their targets. The generalized response mounted by these cells is inflammation, in which neutrophils and macrophages congregate at the site of injury or infection, release toxic substances such as oxygen radicals that damage invaders, and phagocytose both invaders and damaged tissue. Macrophages in particular also release communication molecules, or cytokines, that have broad effects on the organism, including fever and inflammation, and also promote wound healing. These proinflammatory cytokines include interleukin(IL)-1, IL-6, and tumor necrosis factor alpha (TNF). Other granulocytes include the mast cell and the eosinophil, which are involved in parasitic defense and allergy.

Another cell involved in natural immunity is the natural killer cell. Natural killer cells recognize the lack of a self-tissue molecule on the surface of cells (characteristic of many kinds of virally infected and some cancerous cells) and lyse those cells by releasing toxic substances on them. Natural killer cells are thought to be important in limiting the early phases of viral infections, before specific immunity becomes effective, and in attacking self-cells that have become malignant.

Finally, complement is a family of proteins involved in natural immunity. Complement protein bound to microorganisms can up-regulate phagocytosis and inflammation. Complement can also aid in antibody-mediated immunity (discussed below as part of the specific immune response).

Specific immunity is characterized by greater specificity and less speed than the natural immune response. Lymphocytes have receptor sites on their cell surfaces. The receptor on each cell fits with one and only one small molecular shape, or antigen, on a given invader and therefore responds to one and only one kind of invader. When activated, these antigen-specific cells divide to create a population of cells with the same antigen specificity in a process called clonal proliferation, or the proliferative response. Although this process is efficient in terms of the number of cells that have to be supported on a day-to-day basis, it creates a delay of up to several days before a full defense is mounted, and the body must rely on natural immunity to contain the infection during this time.

There are three types of lymphocytes that mediate specific immunity: T-helper cells, T-cytotoxic cells, and B cells. The main function of T-helper cells is to produce cytokines that direct and amplify the rest of the immune response. T-cytotoxic cells recognize antigen expressed by cells that are infected with viruses or otherwise compromised (e.g., cancer cells) and lyse those cells. B cells produce soluble proteins called antibody that can perform a number of functions, including neutralizing bacterial toxins, binding to free virus to prevent its entry into cells, and opsonization, in which a coating of antibody increases the effectiveness of natural immunity. There are five kinds of antibody: Immunoglobulin (Ig) A is found in secretions, IgE binds to mast cells and is involved in allergy, IgM is a large molecule that clears antigen from the bloodstream, IgG is a smaller antibody that diffuses into tissue and crosses the placenta, and IgD is of unknown significance but may be produced by immature B cells.

An important immunological development is the recognition that specific immunity in humans is composed of cellular and humoral responses. Cellular immune responses are mounted against intracellular pathogens like viruses and are coordinated by a subset of T-helper lymphocytes called Th1 cells. In the Th1 response, the T-helper cell produces cytokines, including IL-2 and interferon gamma (IFN). These cytokines selectively activate T-cytotoxic cells as well as natural killer cells. Humoral immune responses are mounted against extracellular pathogens such as parasites and bacteria; they are coordinated by a subset of T-helper lymphocytes called Th2 cells. In the Th2 response, the T-helper cell produces different cytokines, including IL-4 and IL-10, which selectively activate B cells and mast cells to combat extracellular pathogens.

Immune assays can quantify cells, proteins, or functions. The most basic parameter is a simple count of the number of cells of different subtypes (e.g., neutrophils, macrophages), typically from peripheral blood. It is important to have an adequate number of different types of immune cells in the correct proportions. However, the normal range for these enumerative parameters is quite large, so that correct numbers and proportions can cover a wide range, and small changes are unlikely to have any clinical significance in healthy humans.

Protein productioneither of antibody or cytokinescan be measured in vitro by stimulating cells and measuring protein in the supernatant or in vivo by measuring protein in peripheral blood. For both antibody and cytokine, higher protein production may represent a more robust immune response that can confer protection against disease. Two exceptions are levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and antibody against latent virus. Proinflammatory cytokines are increased with systemic inflammation, a risk factor for poorer health resulting from cardiac disease, diabetes mellitus, or osteoporosis (Ershler & Keller, 2000; Luster, 1998; Papanicoloaou, Wilder, Manolagas, & Chrousos, 1998). Antibody production against latent virus occurs when viral replication triggers the immune system to produce antibodies in an effort to contain the infection. Most people become infected with latent viruses such as Epstein-Barr virus during adolescence and remain asymptomatically infected for the rest of their lives. Various processes can activate these latent viruses, however, so that they begin actively replicating. These processes may include a breakdown in cellular immune response (Jenkins & Baum, 1995). Higher antibody against latent viruses, therefore, may indicate poorer immune control over the virus.

Functional assays, which are performed in vitro, measure the ability of cells to perform specific activities. In each case, higher values may represent more effective immune function. Neutro-phils function can be quantified by their ability to migrate in a laboratory assay and their ability to release oxygen radicals. The natural killer cytotoxicity assay measures the ability of natural killer cells to lyse a sensitive target cell line. Lymphocyte proliferation can be stimulated with mitogens that bypass antigen specificity to activate cells or by stimulating the T cell receptor.

How could stress get inside the body to affect the immune response? First, sympathetic fibers descend from the brain into both primary (bone marrow and thymus) and secondary (spleen and lymph nodes) lymphoid tissues (Felten & Felten, 1994). These fibers can release a wide variety of substances that influence immune responses by binding to receptors on white blood cells (Ader, Cohen, & Felten, 1995; Felten & Felten, 1994; Kemeny, Solomon, Morley, & Herbert, 1992; Rabin, 1999). Though all lymphocytes have adrenergic receptors, differential density and sensitivity of adrenergic receptors on lymphocytes may affect responsiveness to stress among cell subsets. For example, natural killer cells have both high-density and high-affinity 2-adrenergic receptors, B cells have high density but lower affinity, and T cells have the lowest density (Anstead, Hunt, Carlson, & Burki, 1998; Landmann, 1992; Maisel, Fowler, Rearden, Motulsky, & Michel, 1989). Second, the hypothalamicpituitaryadrenal axis, the sympatheticadrenalmedullary axis, and the hypothalamicpituitaryovarian axis secrete the adrenal hormones epinephrine, norepinephrine, and cortisol; the pituitary hormones prolactin and growth hormone; and the brain peptides melatonin, -endorphin, and enkephalin. These substances bind to specific receptors on white blood cells and have diverse regulatory effects on their distribution and function (Ader, Felten, & Cohen, 2001). Third, peoples efforts to manage the demands of stressful experience sometimes lead them to engage in behaviorssuch as alcohol use or changes in sleeping patternsthat also could modify immune system processes (Kiecolt-Glaser & Glaser, 1988). Thus, behavior represents a potentially important pathway linking stress with the immune system.

Maier and Watkins (1998) proposed an even closer relationship between stress and immune function: that the immunological changes associated with stress were adapted from the immunological changes in response to infection. Immunological activation in mammals results in a syndrome called sickness behavior, which consists of behavioral changes such as reduction in activity, social interaction, and sexual activity, as well as increased responsiveness to pain, anorexia, and depressed mood. This syndrome is probably adaptive in that it results in energy conservation at a time when such energy is best directed toward fighting infection. Maier and Watkins drew parallels between the behavioral, neuroendo-crine, and thermoregulatory responses to sickness and stress. The common thread between the two is the energy mobilization and redirection that is necessary to fight attackers both within and without.

Conceptualizations of the nature of the relationship between stress and the immune system have changed over time. Selyes (1975) finding of thymic involution led to an initial model in which stress is broadly immunosuppressive. Early human studies supported this model, reporting that chronic forms of stress were accompanied by reduced natural killer cell cytotoxicity, suppressed lymphocyte proliferative responses, and blunted humoral responses to immunization (see S. Cohen, Miller, & Rabin, 2001; Herbert & Cohen, 1993;Kiecolt-Glaser, Glaser, Gravenstein, Malarkey, & Sheridan, 1996, for reviews). Diminished immune responses of this nature were assumed to be responsible for the heightened incidence of infectious and neoplastic diseases found among chronically stressed individuals (Andersen, Kiecolt-Glaser, & Glaser, 1994; S. Cohen & Williamson, 1991).

Although the global immunosuppression model enjoyed long popularity and continues to be influential, the broad decreases in immune function it predicts would not have been evolutionarily adaptive in life-threatening circumstances. Dhabhar and McEwen (1997, 2001) proposed that acute fight-or-flight stressors should instead cause redistribution of immune cells into the compartments in which they can act the most quickly and efficiently against invaders. In a series of experiments with mice, they found that during acute stress, T cells selectively redistributed into the skin, where they contributed to enhancement of the immune response. In contrast, during chronic stress, T cells were shunted away from the skin, and the immune response to skin test challenge was diminished (Dhabhar & McEwen, 1997). On the basis of these findings they proposed a biphasic model in which acute stress enhances, and chronic stress suppresses, the immune response.

A modification of this model posits that short-term changes in all components of the immune system (natural and specific) are unlikely to occur because they would expend too much energy to be adaptive in life-threatening circumstances. Instead, stress should shift the balance of the immune response toward activating natural processes and diminishing specific processes. The premise underlying this model is that natural immune responses are better suited to managing the potential complications of life-threatening situations than specific immune responses because they can unfold much more rapidly, are subject to fewer inhibitory constraints, and require less energy to be diverted from other bodily systems that support the fight-or-flight response (Dopp, Miller, Myers, & Fahey, 2000; Sapolsky, 1998).

Even with this modification of the biphasic model, neither it nor the global immunosuppression model sufficiently explains findings that link chronic stress with both disease outcomes associated with inadequate immunity (infectious and neoplastic disease) and disease outcomes associated with excessive immune activity (allergic and autoimmune disease). To resolve this paradox, some researchers have chosen to focus on how chronic stress might shift the balance of the immune response. The most well-known of these models hypothesizes that chronic stress elicits simultaneous enhancement and suppression of the immune response by altering patterns of cytokine secretion (Marshall et al., 1998). Th1 cytokines, which activate cellular immunity to provide defense against many kinds of infection and some kinds of neoplastic disease, are suppressed. This suppression has permissive effects on production of Th2 cytokines, which activate humoral immunity and exacerbate allergy and many kinds of autoimmune disease. This shift can occur via the effects of stress hormones such as cortisol (Chiappelli, Manfrini, Franceschi, Cossarizza, & Black, 1994). Th1-to-Th2 shift changes the balance of the immune response without necessarily changing the overall level of activation or function within the system. Because a diminished Th1-mediated cellular immune response could increase vulnerability to infectious and neoplastic disease, and an enhanced Th-2 mediated humoral immune response could increase vulnerability to autoimmune and allergic diseases, this cytokine shift model also is able to reconcile patterns of stress-related immune change with patterns of stress-related disease outcomes (Marshall et al., 1998).

If the stress response in the immune system evolved, a healthy organism should not be adversely affected by activation of this response because such an effect would likely have been selected against. Although there is direct evidence that stress-related immunosuppression can increase vulnerability to disease in animals (e.g., Ben Eliyahu, Shakhar, Page, Stefanski, & Shakhar, 2000; Quan et al., 2001; Shavit et al., 1985; Sheridan et al., 1998), there is little or no evidence linking stress-related immune change in healthy humans to disease vulnerability. Even large stress-induced immune changes can have small clinical consequences because of the redundancy of the immune systems components or because they do not persist for a sufficient duration to enhance disease susceptibility. In short, the immune system is remarkably flexible and capable of substantial change without compromising an otherwise healthy host.

However, the flexibility of the immune system can be compromised by age and disease. As humans age, the immune system becomes senescent (Boucher et al., 1998; Wikby, Johansson, Ferguson, & Olsson, 1994). As a consequence, older adults are less able to respond to vaccines and mount cellular immune responses, which in turn may contribute to early mortality (Ferguson, Wikby, Maxson, Olsson, & Johansson, 1995; Wayne, Rhyne, Garry, & Goodwin, 1990). The decreased ability of the immune system to respond to stimulation is one indicator of its loss of flexibility.

Loss of self-regulation is also characteristic of disease states. In autoimmune disease, for example, the immune system treats self-tissue as an invader, attacking it and causing pathology such as multiple sclerosis, rheumatoid arthritis, Crohns disease, and lupus. Immune reactions can also be exaggerated and pathological, as in asthma, and suggest loss of self-regulation. Finally, infection with HIV progressively incapacitates T-helper cells, leading to loss of the regulation usually provided by these cells. Although each of these diseases has distinct clinical consequences, the change in the immune system from flexible and balanced to inflexible and unbalanced suggests increased vulnerability to stress-related immune dysregulation; furthermore, dysregulation in the presence of disease may have clinical consequences (e.g., Bower, Kemeny, Taylor, & Fahey, 1998).

We performed a meta-analysis of published results linking stress and the immune system. We feel that this area is in particular need of a quantitative review because of the methodological nature of most studies in this area. For practical and economic reasons, many psychoneuroimmunology studies have a relatively small sample size, creating the possibility of Type II error. Furthermore, many studies examine a broad range of immunological parameters, creating the possibility of Type I error. A quantitative review, of which meta-analysis is the best example, can better distinguish reliable effects from those arising from both Type I and Type II error than can a qualitative review.

We combined studies in such a way as to test the models of stress and immune change reviewed above. First, we examined each stressor type separately, yielding separate effects for stressors of different duration and trajectory. Second, we examined both healthy and medical populations, allowing comparison of the effects of stress on resilient and vulnerable populations; along the same lines, we also examined the effects of age. Finally, we examined all immune parameters separately so that patterns of response (e.g., global immunosuppression vs. cytokine shift) would be clearer.

Articles for the meta-analysis were identified through computerized literature searches and searches of reference lists. MEDLINE and PsycINFO were searched for the years 1960 2001. Following the example of Herbert and Cohen (1993), we used the terms stress, hassles, and life events in combination with the term immune to search both databases. The reference lists of 11 review articles on stress and the immune system (Benschop, Geenen, et al., 1998; Biondi, 2001; Cacioppo, 1994; S. Cohen & Herbert, 1996; S. Cohen et al., 2001; Herbert & Cohen, 1993; Kiecolt-Glaser, Cacioppo, Malarkey, & Glaser, 1992; Kiecolt-Glaser, McGuire, Robles, & Glaser, 2002; Maier, Watkins, & Fleshner, 1994; OLeary, 1990; Zorrilla et al., 2001) were then searched to identify additional articles.

We selected only articles that met a number of inclusion criteria. The first criterion was that the work had to include a measure of stress. This criterion could be met if a sample experiencing a stressor was compared with an unstressed control group, if a sample experiencing a stressor was compared with itself at a baseline that could reasonably be considered low stress, or if differing degrees of stress in a sample were assessed with an explicit measure of stress. This criterion was not met if, for example, anxietyan affective statewas used as a proxy for stress, or it seemed likely that a baseline assessment occurred during periods of significant stress. The second criterion was that the stressor had to be psychosocial. Stressors that included a significant physical element such as pain, cold, or physical exhaustion were eliminated (e.g., Antarctic isolation, space flight, military training). The third criterion was that the work had to include a measure of the immune system. This criterion was met by any enumerative or functional in vitro or in vivo immune assay. However, clinical disease outcomes such as HIV progression or rhinovirus infection did not meet this criterion. Finally, we eliminated articles from which a meaningful effect size could not be abstracted. For example, when between- and within-subjects observations were treated as independent, the reported effect was likely to be inflated. In a few cases, effects of stress and clinical status were confoundedthat is, a stressed clinical group was compared with an unstressed healthy groupand hence these studies were excluded from the meta-analysis.

We coded stressors in the articles into five classes: acute time-limited, brief naturalistic, event sequence, chronic, and distant. The most difficult distinctions among event sequence, chronic, and distant stressors were based on temporal and qualitative considerations. Event sequences included discrete stressors occurring 1 year or less before immune assessment and could be of any severity. These were most often normative stressors such as bereavement. Chronic stressors were ongoing stressors such as caregiving and disability. Distant stressors were severe, traumatic events that could meet the stressor criterion for posttraumatic stress disorder (American Psychiatric Association, 1994), such as combat exposure or abuse, and had happened more than 1 year before immune assessment. Most stressors in this category occurred 5 to 10 years before immune assessment. Disagreements in stressor classification were resolved by consensus. Subgroups for moderator analyses were similarly decided.

Meta-analysis is a tool for synthesizing research findings. It proceeds in two phases. In the first, effect sizes are computed for each study. An effect size represents the magnitude of the relationship between two variables, independent of sample size. In this context it can be viewed as a measure of how much two groups, one experiencing a stressor and the other not, differ on a specific immune outcome. In the second phase, effect sizes from individual studies are combined to arrive at an aggregate effect size for each immune outcome of interest.

We used Pearsons r as the effect size metric in this meta-analysis. Effect sizes for individual studies were computed using descriptive statistics presented in the original published reports. When these statistics were not available, we requested them from authors. This strategy was successful in most circumstances. To compute Pearsons r from descriptive statistics in between-subjects designs, we subtracted the control group mean from the stressed group mean and divided this value by the pooled sample standard deviation. The value that emerged from this computation, known as Cohens d, was then converted into a Pearsons r by taking the square root of the quantity d2/(d2 + 4). (See Rosenthal, 1994.) To compute Pearsons r from descriptive statistics in within-subjects designs, we subtracted the group mean at baseline from the group mean during stress and divided this quantity by the sample standard deviation at baseline. This d value was converted into a Pearsons r by taking the square root of the quantity d2/(d2 + 4). In cases in which descriptive statistics were not available, Pearsons r was computed from inferential statistics using standard formulae (Rosenthal, 1994). These formulae had to be modified slightly for studies that used within-subjects designs because effect sizes are systematically overestimated when they are calculated from repeated measures test statistics (Dunlap, Cortina, Vaslow, & Burke, 1996). In these situations we derived effect size estimates using the formula d = tc[2 (1 r)]1/2, where tc corresponds to the value of the t statistic for correlated measures, and r corresponds to the value of the correlation between outcome measures at pretest and posttest (Dunlap et al., 1996). Because very few studies reported the value of r, we used a value of .60 to compute effect sizes in this meta-analysis. This represents the average correlation between pre-stress and poststress measures of immune function in a series of studies performed in our laboratories. To ensure that the meta-analytic findings were robust to variations in r, we conducted follow-up analyses using r values ranging from .45 to .75. Very similar findings emerged from these analyses, suggesting that the values we present below are reliable estimates of effect size. If anything, they are probably conservative estimates, because the prepost correlation between immune measures often is substantially lower than .60.

The effect size estimates from individual studies were subsequently aggregated using random-effects models with the software program Comprehensive Meta-Analysis (Borenstein & Rothstein, 1999). The random-effects model views each study in a meta-analysis as a random observation drawn from a universe of potential investigations. As such, it assumes that the magnitude of the relationship between stress and the immune system differs across studies as a result of random variance associated with sampling error and differences across individuals in the processes of interest. Because of these assumptions, random-effects models not only permit one to draw inferences about studies that have been done but also to generalize to studies that might be done in the future (Raudenbush, 1994; Shadish & Haddock, 1994). It also bears noting that in the population of studies on stress and immunity there is likely to be a fair amount of nonrandom variance, as researchers who examine ostensibly similar phenomena may still differ in terms of the samples they recruit, the operational definition of stress they use, and the laboratory methods they utilize to assess a specific immune process.

Separate random-effects models were computed for each immune outcome included in the meta-analysis. Prior to computing the random-effects model, r values derived from each study were z-transformed by the software program, as recommended by Shadish and Haddock (1994), to stabilize variance. The z values were later back-transformed into r values to facilitate interpretation of the meta-analytic findings. In the end, each random-effects model yielded an aggregate weighted effect size r, which can be interpreted the same way as a correlation coefficient, ranging in value from 1.00 to 1.00. Each r statistic was weighted before aggregation by multiplying its value by the inverse of its variance; this procedure enabled larger studies to contribute to effect size estimates to a greater extent than smaller ones. Weighting effect sizes is important because larger studies provide more accurate estimates of true population parameters (Shadish & Haddock, 1994). After each aggregate effect size had been derived, we computed 95% confidence intervals around it, assessed whether it was statistically significant, and computed a heterogeneity coefficient to determine whether the studies contributing to it had yielded consistent findings. Following convention, aggregate effect sizes were considered statistically different from zero when (a) their corresponding z value was greater than 1.96 and (b) the 95% confidence intervals around them did not include the value zero (Rosenthal, 1991; Shadish & Haddock, 1994).

To determine whether the studies contributing to each aggregate effect size shared a common population value, we computed the heterogeneity statistic Q (Shadish & Haddock, 1994). This statistic is chi-square distributed with k 1 degrees of freedom, where k represents the number of independent effect sizes included. When a statistically significant heterogeneity test emerged, we searched for moderators (characteristics of the participants, stressful experience, or measurement strategy) that could explain the variability across studies. The first step in this process involved estimating correlations between participant characteristics (e.g., mean age, percentage female) and immune effects to examine whether the strength of effects varied according to demographics. When it was possible to do so, we then stratified the studies according to characteristics of the stressful experience (e.g., duration, quality) or the measurement strategy (e.g., interview, checklist), and computed separate random-effects analyses for each subgroup.

Occasionally authors of studies failed to report the descriptive or inferential statistics needed to compute an effect size. In some of these cases, the authors noted that there was a significant difference between a stressed and control group. When this occurred, we computed effect sizes assuming that p values were equivalent to .05. This represents a conservative approach because the actual p values were probably smaller. In other cases, the authors noted that a stressed and control group did not differ with respect to an immune outcome, but failed to provide any further statistical information. When this occurred, we computed effect sizes assuming that there was no difference at all between the groups (r = .00). Because there is seldom no difference at all between two groups, this also represents a conservative strategy. Imputation was used in less than 7% of cases.

The validity of a meta-analysis rests on the assumption that each value contributing an aggregate effect size is statistically independent of the others (Rosenthal, 1991). We devised a number of strategies to avoid violating this independence assumption. First, in studies that assessed stimulated-lymphocyte proliferation at multiple mitogen dosages, we computed the average effect size across mitogen dosages, and we used this value to derive aggregate indices. We used an analogous strategy for studies that assessed natural killer cell cytotoxicity at multiple effector:target cell ratios. Second, in studies that utilized designs in which multiple laboratory stressors were compared with a control condition, the average effect size across stressor conditions was computed and later used to derive aggregate indices. Because this averaging procedure in most cases yielded an effect size that was smaller than that of the most potent stressor, we also computed meta-analyses using the larger of the effect sizes from each study rather than the average. Doing so did not alter any of the substantive findings we report. Third, in studies in which immune outcomes were assessed on multiple occasions during a stressful experience, the average effect size across occasions was used to derive aggregate indices. Note that we did not conduct meta-analyses of recovery effects, that is, immune values after a stressor had ended. Although such an analysis would answer interesting questions about the stress-recovery process, there were not enough studies that included similar immune outcomes assessed at similar time points after stress to permit a complete analysis. Fourth, because some data were published in more than one outlet, we contacted authors of multiple publications to determine sample independence or dependence.

The meta-analysis is based on effect sizes derived from 293 independent studies. These studies were reported in 319 separate articles in peer-reviewed scientific journals (see ). A total of 18,941 individuals participated in these studies. Their mean age was 34.8 years (SD = 15.9). Although the studies collectively included a broad range of age groups (range = 578 years), most focused heavily on younger adults. More than half of the studies (51.3%) had a mean age under 30.0 years, and more than four fifths (84.8%) had a mean age under 55.0 years. Slightly more than two thirds of the studies (68.5%) included women; in the average study almost half (42.8%) of the participants were female. The vast majority of studies (84.8%) focused on medically healthy adults.2 Of those that included medical populations, most focused on HIV/AIDS (k = 18; 38.3%), arthritis (k = 6; 12.8%), cancer (k = 5; 10.6%), or asthma (k = 4; 8.5%).

Studies Used in the Meta-Analysis by Type of Stressor

With respect to the kinds of stressors examined by studies in the meta-analysis, the most commonly utilized models were acute laboratory challenges (k = 85; 29.0%) and brief naturalistic stressors (k = 63; 21.5%). Stressful event sequences (k = 30; 10.2%), chronic stressors (k = 23; 7.8%), and distant traumatic experiences (k = 9; 3.1%) were explored less frequently. More than a quarter of the studies in the meta-analysis modeled the stress process by administering nonspecific life-event checklists (k = 53; 18.1%) and/or global perceived stress measures (k = 21; 7.1%) to participants. A small minority of studies examined whether reports of perceived stress or intrusive memories were associated with the extent of immune dysregulation within populations who had suffered a specific traumatic experience (k = 9; 3.1%).

The studies in the meta-analysis examined 292 distinct immune system outcomes. A minority of these outcomes were assessed in three or more studies (k = 87; 30.0%), and as such, they are the focus of the meta-analyses we present in the rest of this article (see ). The most commonly assessed enumerative outcomes were counts of T-helper lymphocytes (k = 90; 30.7%), T-cytotoxic lymphocytes (k = 81; 27.6%), natural killer cells (k = 67; 22.9%), and total lymphocytes (k = 52; 17.7%). The most commonly assessed functional outcomes were natural killer cell cytotoxicity (k = 94; 32.1%) and lymphocyte proliferation stimulated by the mitogens phytohemagglutinin (PHA; k = 65; 22.2%), concanavalin A (ConA; k = 39; 13.3%), and pokeweed mitogen (PWM; k = 26; 8.9%).

lists the immune parameters analyzed with the arm of the immune system to which they belong (natural or specific) and, briefly, their function. Where relevant, cell surface markers used to identify classes of immunocytes in flow cytometry are given. For example, the cell surface marker CD19 is used to identify B lymphocytes. Recall that different models of stress and the immune system posit differential effects of stress on subsets of the immune systemfor example, natural versus specific immunity or cellular (Th1) versus humoral (Th2) immunity. acts as a guide for interpreting the pattern of results in light of these models.

In the following sections we describe the meta-analytic results for each stressor category. A useful rule of thumb for judging effect sizes is to consider values of .10, .30, and .50 as corresponding to small, medium, and large effects, respectively (J. Cohen & Cohen, 1983); more generally, the aggregate effect size r can be interpreted in the same fashion as a correlation, with values ranging from 1.00 to 1.00. Positive values indicate that the presence of a stressor increases a particular immune parameter relative to some baseline (or control) condition. We should caution the reader that in some analyses, our statistics are derived from as few as three independent studies. Although meta-analyses of small numbers of studies do not pose any major statistical problems, it is important to remember that they have limited power to detect statistically significant effect sizes. What a meta-analysis can accurately provide in these instances, however, is an estimate of how much and what direction a given stressors presence influences a specific immune outcome (i.e., an effect size estimate).

Acute time-limited stressors included primarily experimental manipulations of stressful experiences, such as public speaking and mental arithmetic, that lasted between 5 and 100 min. Reliable effects on the immune system included increases in immune parameters, especially natural immunity. The most robust effect of this kind of experience was a marked increase in the number of natural killer cells (r =.43) and large granular lymphocytes (r =.53) in peripheral blood (see ). This effect is consistent with the view that acute stressors cause immune cells to redistribute into the compartments in which they will be most effective (Dhabhar & McEwen, 1997). However, other types of lymphocytes did not show robust redistribution effects: B cells and T-helper cells showed very little change (rs = .07 and .01, respectively), and this change was not statistically significant across studies. T-cytotoxic lymphocytes did tend to increase reliably in peripheral blood, though to a lesser degree than their natural immunity counterparts (r =.20); this increase drove a reliable decline in the T-helper:T-cytotoxic ratio (r = .23). However, natural killer cells as well as T-cytotoxic cells can express CD8, the marker most often used to define the latter population. Because some studies did not use the T cell receptor (CD3) to differentiate between CD3CD8+ natural killer cells and CD3+CD8+ T-cytotoxic cells, it is possible that the effect for T-cytotoxic cells is actually being driven by natural killer cells (Benschop, Rodriguez-Feuerhahn, & Schedlowski, 1996).

Meta-Analysis of Immune Responses to Acute Time-Limited Stress in Healthy Participants

The results for cell percentages roughly parallel those for number. However, the percentage data are harder to interpret because any given parameter is linearly dependent on the other parameters: For example, the enumerative data suggest that the decrease in percentage T-helper cells (r = .24) is probably an artifact of the increases in percentage natural killer cells (r = .24) and percentage T-cytotoxic cells (r = .09).

Another effect that may be considered a redistribution effect is the significant increase in secretory IgA in saliva (r = .22). The time frame of these acute stressors is too short for the synthesis of a significant amount of new antibody; therefore, this increase is probably due to release of already-synthesized antibody from plasma cells and increased translocation of antibody across the epithelium and into saliva (Bosch, Ring, de Geus, Veerman, & Amerongen, 2002). This effect therefore represents relocation, albeit of an immune protein rather than an immune cell.

There were also a number of functional effects. First, natural killer cell cytotoxicity significantly increased with acute stressors (r = .30), but only when the concomitant increase in proportion of natural killer cells in the effector mix was not removed statistically. When examined on a per-cell basis, cytotoxicity did not significantly increase (r = .12). One could, therefore, consider the increase in cytotoxicity a methodological artifact of the definition of effector in effector:target ratios. However, to the degree that one is interested in the general cytotoxic potential of the contents of peripheral blood rather than that of a specific natural killer cell, the uncorrected value is more illustrative. Second, mitogen-stimulated proliferative responses decreased significantly. Again, this could be a methodological artifact of the mix of cells in the assay. However, the proportion of total T and B cells, which are responsible for the proliferative response to PWM and ConA, did not decrease as reliably or as much as did the proliferative response (rs = .05 to .11 vs. .10 to .17), suggesting that acute stressors do decrease this function of specific immunity. Finally, the production of two cytokines, IL-6 and IFN, was increased significantly following acute stress (rs = .28 and .21, respectively).

The data for acute stressors, therefore, support an upregulation of natural immunity, as reflected by increased number of natural killer cells in peripheral blood, and potential downregulation of specific immunity, as reflected by decreased proliferative responses. Other indicators of upregulated natural immunity include increased neutrophil numbers in peripheral blood (r = .30), increased production of a proinflammatory cytokine (IL-6), and increased production of a cytokine that potently stimulates macrophages and natural killer cells as well as T cells (IFN). The only exception to this pattern was the increased secretion of IgA antibody, which is a product of the specific immune response. An interesting question for future research is whether this effect is part of a larger nonspecific protein release in the oral cavity in response to acute stress (cf. Bosch et al., 2002).

It bears noting that a number of the findings presented in are accompanied by significant heterogeneity statistics. To identify moderating variables that might explain some of this heterogeneity, we examined whether effect sizes varied according to demographic characteristics of the sample (mean age and percentage female) or features of the acute challenge (its duration and nature). Neither of the demographic characteristics showed a consistent relationship with immune outcomes. Although these findings suggest that acute time-limited stressors elicit a similar pattern of immune response for men and women across the life span, this conclusion needs to be viewed somewhat cautiously given the narrow range of ages found in these studies. We also did not find a consistent pattern of relationships between features of the acute challenge and immune outcomes. Acute stressors elicited similar patterns of immune change across a wide spectrum of durations ranging from 5 though 100 min and irrespective of whether they involved social (e.g., public speaking), cognitive (e.g., mental arithmetic), or experiential (e.g., parachute jumping) forms of stressful experience.

presents the meta-analysis of brief naturalistic stressors for medically healthy adults. The vast majority of these stressors (k = 60; 95.2%) involved students facing academic examinations. In contrast to the acute time-limited stressors, examination stress did not markedly affect the number or percentage of cells in peripheral blood. Instead, the largest effects were on functional parameters, particularly changes in cytokine production that indicate a shift away from cellular immunity (Th1) and toward humoral immunity (Th2). Brief stressors reliably changed the profile of cytokine production via a decrease in a Th1-type cytokine, IFN (r = .30), which stimulates natural and cellular immune functions, and increases in the Th2-type cytokines IL-6 (r = .26), which stimulates natural and humoral immune functions, and IL-10 (r = .41), which inhibits Th1 cytokine production. Note that IFN and IL-6 share the property of stimulating natural immunity but differentially stimulate cytotoxic versus inflammatory effector mechanisms. Their dissociation after brief naturalistic stress indicates differential effects between Th1 and Th2 responses rather than natural and specific responses.

Meta-Analysis of Immune Responses to Brief Naturalistic Stress in Healthy Participants

The functional assay data are consistent with this suggestion of suppression of cellular immunity via decreased Th1 cytokine production: The T cell proliferative response significantly decreased with brief stressors (r = .19 to .32), as did natural killer cell cytotoxicity (r = .11). Increased antibody production to latent virus, particularly Epstein-Barr virus (r = .20), is also consistent with suppression of cellular immunity, enhancement of humoral immunity, or both.

There was also evidence that age contributed to vulnerability to stress-related immune change during brief naturalistic stressors, even within a limited range of relatively young ages. When we examined whether effect sizes varied according to demographic characteristics of the sample, sex ratio did not show a consistent pattern of relations with immune processes. However, the mean age of the sample was strongly related to study effect size. To the extent that a study enrolled participants of older ages, it was likely to observe more pronounced decreases in natural killer cell cytotoxicity (r = .58, p = .04; k = 14), T lymphocyte proliferation to the mitogens PHA (r = .58, p = .04; k = 13) and ConA (r = .31, p = .38; k = 9), and production of the cytokine IFN (r = .63, p = .09; k = 8) in response to brief naturalistic stress. The strength of these findings is particularly surprising given the narrow range of ages found in studies of brief natural stress; the mean participant age in this literature ranged from 15.7 to 35.0 years.

We also calculated effect sizes for three studies examining the effects of examination stress on individuals with asthma (see ). These three studies, all emanating from a team of investigators at the University of WisconsinMadison, found that stress reliably increased superoxide release (r = .20 to .37) and decreased natural killer cell cytotoxicity (r = .33). Because natural killer cells are stimulated by Th1 cytokines, this change is consistent with a Th1-to-Th2 shift. However, stress also reliably increased T cell proliferation to PHA (r = .32), which is not consistent with such a shift. The generally larger effect sizes are consistent with the idea that individuals with immunologically mediated disease are more susceptible to stress-related immune dysregulation, but the reversed sign for T cell proliferation also indicates that that pattern of dysregulation may also be more disorganized. That is, the organized pattern of suppression of Th1 but not Th2 immune responses in healthy individuals undergoing brief stressors may reflect regulation in the healthy immune system. In contrast, the lack of regulation in a diseased immune system may lead to more chaotic changes during stressors.

Meta-Analysis of Immune Responses to Brief Naturalistic Stress in Participants With Asthma

The meta-analysis of stressful event sequences is presented in . With the exception of significant increases in the number of circulating natural killer cells and the number of antibodies to the latent Epstein-Barr virus, the findings indicate that stressful event sequences are not associated with reliable immune changes. For many immune outcomes, however, significant heterogeneity statistics are evident. Studies of healthy adults generally fell into two categories that yielded disparate patterns of immune findings. The largest group of studies focused on the death of a spouse as a stressor and, as such, used samples consisting primarily of older women. Collectively, these studies found that losing a spouse was associated with a reliable decline in natural killer cell cytotoxicity (r = .23, p = .01; k = 6) but not with alterations in stimulated-lymphocyte proliferation by the mitogens ConA (r = .04, p = .45; k = 4), PHA (r = .01, p = .93; k = 7), or PWM (r = .08, p = .76; k = 3) or with changes in the number of T-helper lymphocytes (r = .07, p = .52; k = 6) or T-cytotoxic lymphocytes (r = .13, p = .45; k = 5) in peripheral blood. The next largest group of studies in this area examined immune responses to disasters, which may have different neuroendocrine consequences than loss; whereas loss is generally associated with increases in cortisol, trauma may be associated with decreases in cortisol (Yehuda, 2001; Yehuda, McFarlane, & Shalev, 1998). Natural disaster samples tended to focus on middle-aged adults of both sexes who were direct victims of the disaster, rescue workers at the scene, or personnel at nearby medical centers. There were medium-size effects suggesting increases in natural killer cell cytotoxicity (r = .25, p = .53; k = 4) and stimulated-lymphocyte proliferation by the mitogen PHA (r = .26, p = .33; k = 2), as well as decreases in the number of T-helper lymphocytes (r = .20, p = .43; k = 2) and T-cytotoxic lymphocytes (r = .23, p = .55; k = 2) in the circulation. However, none of them was statistically significant because of the small number of studies involved, and therefore these effects should be considered suggestive but not reliable.

Meta-Analysis of Immune Responses to Stressful Event Sequences in Healthy Participants

An additional group of studies in this area examined immune responses to a positive initial biopsy for breast cancer in primarily middle-aged female participants before and after the procedure. The three studies of this nature did not yield a consistent pattern of relations with any of the immune outcomes.

In summary, stressful event sequences did not elicit a robust pattern of immune changes when considered as a whole. When these sequences are broken down into categories reflecting the stressors nature, the meta-analysis yields evidence of declines in natural immune response following the loss of a spouse, nonsignificant increases in natural and specific immune responses following exposure to natural disaster, and no immune alterations with breast biopsy. Unfortunately, we cannot determine whether these disparate patterns of immune response are attributable to features of the stressors, demographic or medical characteristics of the participants, or some interaction between these factors.

Chronic stressors included dementia caregiving, living with a handicap, and unemployment. Like other nonacute stressors, they did not have any systematic relationship with enumerative measures of the immune system. They did, however, have negative effects on almost all functional measures of the immune system (see ). Both natural and specific immunity were negatively affected, as were Th1 (e.g., T cell proliferative responses) and Th2 (e.g., antibody to influenza vaccine) parameters. The only nonsignificant change was for antibody to latent virus; this effect size was substantial (r = .44), but there was also substantial heterogeneity. Further analyses showed that demographics did not moderate this effect: Immune responses to chronic stressors were equally strong across the age spectrum as well as across sex.

Meta-Analysis of Immune Responses to Chronic Stress in Healthy Participants

Distant stressors were traumatic events such as combat exposure or abuse occurring years prior to immune assessment. The meta-analytic results for distant stressors appear in . The only immune outcome that has been examined regularly in this literature is natural killer cell cytotoxicity, and it is not reliably altered in persons who report a distant traumatic experience.

Meta-Analysis of Immune Responses to Distant Stressors and Posttraumatic Stress Disorder in Healthy Participants

Most of the studies in this area examined whether immune responses varied as a function of the number of life events a person endorsed on a standard checklist, a persons rating of the impact of those events, or both. As illustrates, this methodology yielded little in the way of significant outcomes in healthy participants. To determine whether vulnerability to life events might vary across the life span, we divided studies into two categories on the basis of a natural break in the age distribution. These analyses provided evidence that older adults are especially vulnerable to life-eventinduced immune change. In studies that used samples of adults who had a mean age above 55, life events were associated with reliable declines in lymphocyte-proliferative responses to PHA (r = .40, p = .05; k = 2) and natural killer cell cytotoxicity (r = .59, p = .001; k = 2). These effects were much weaker in studies with a mean age below 55: Life events were not associated with proliferative responses to PHA (r = .22, p = .24; k = 2), and showed a reliable but modest relationship with natural killer cell cytotoxicity (r = .10, p = .03; k = 8). The differences in effect size between older and younger adults were statistically significant for natural killer cell cytotoxicity ( p < .001) but not PHA-induced proliferation ( p <.15). None of the other moderators we examinedsex ratio, kind of life event assessed (daily hassle vs. major event), or the method used to do so (checklist vs. interview)was related to immune outcomes.

Meta-Analysis of Immune Responses to Major and Minor Life Events of Unknown Duration in Healthy Participants

presents the relationship between life events and immune parameters in participants with HIV/AIDS. The presence of life events was associated with a significant reduction in the number of natural killer cells and a marginal reduction in the number of T-cytotoxic lymphocytes. It is unrelated to the number of T-helper lymphocytes, the percentage of T-cytotoxic lymphocytes, and the T-helper:T-cytotoxic ratio, all of which are recognized indicators of disease progression for patients with HIV/AIDS.

Meta-Analysis of Immune Responses to Major and Minor Life Events of Unknown Duration in Participants With HIV/AIDS

We have already proposed that immunological disease diminishes the resilience and self-regulation of the immune system, making it more vulnerable to stress-related disruption, and this may be the case in HIV-infected versus healthy populations. However, studies of HIV-infected populations also utilized more refined measures of life events (interviews that factor in biographical context) than did studies of healthy populations (typically, checklist measures). Unfortunately, we cannot differentiate between these explanations on the basis of the available data.

The meta-analysis of stress appraisals and intrusive thoughts is displayed in . These studies generally enrolled large populations of adults who were not experiencing any specific form of stress and examined whether their immune responses varied according to stress appraisals and/or intrusive thoughts. This methodology was unsuccessful at documenting immune changes related to stress. Because of the small number of studies in this category, moderator analyses could not be performed.

Meta-Analysis of Immune Responses to Global Stress Appraisals in Healthy Participants

The meta-analysis results shown in address a similar question with regard to persons who are in the midst of a specific event sequence or a chronic stressor. To the extent that they appraise their lives as stressful or report the occurrence of intrusive thoughts, these individuals exhibit a significant reduction in natural killer cell cytotoxicity. Although this effect does not extend to the number of T-helper and T-cytotoxic lymphocytes in the circulation, it suggests that a persons subjective representation of a stressor may be a determinant of its impact on the immune response.

Meta-Analysis of Immune Responses to Stress Appraisals and Intrusive Thoughts Within Healthy Stressed Populations

The large number of effect sizes generated by the meta-analysis raises the possibility of Type I error. One strategy for evaluating this concern involves dividing the number of significant findings in a meta-analysis by the total number of analyses conducted. When we performed this calculation, a value of 25.6% emerged, suggesting that more than one fourth of the analyses yielded reliable findings. This exceeds the 5% value at which investigators typically become concerned about Type I error rates and gives us confidence that the meta-analytic findings presented here are robust.

A second concern arises from the publication bias toward positive findings, which could skew meta-analytic results toward larger effect sizes. Fortunately, recent advances in meta-analysis enable one to evaluate the extent of this publication bias by using graphical techniques. A funnel plot can be drawn in which effect sizes are plotted against sample sizes for any group of studies. Because most studies in any given area have small sample sizes and therefore tend to yield more variable findings, the plot should end up looking like a funnel, with a narrow top and a wide bottom. If there is a bias against negative findings in an area, the plot is shifted toward positive values or a chunk of it will be missing entirely.

We drew funnel plots for all of the immune outcomes in the meta-analysis for which there were a sufficient number of observations. Although not all of them yielded perfect funnels, there was no systematic evidence of publication bias. Space limitations prevent us from including all plots; however, displays three plots that are prototypical of those we drew. As is evident from the data in the figure, psychoneuroimmunology researchers seem to be reporting positive and negative findingsand not hiding unfavorable outcomes when they do emerge. Thus, we do not have any major concerns about publication bias leading this meta-analysis to dramatically overestimate effect sizes.

Funnel plots depicting relationship between effect size and sample size. PHA = phytohemagglutinin.

The immune system, once thought to be autonomous, is now known to respond to signals from many other systems in the body, particularly the nervous system and the endocrine system. As a consequence, environmental events to which the nervous system and endocrine system respond can also elicit responses from the immune system. The results of meta-analysis of the hundreds of research reports generated by this hypothesis indicate that stressful events reliably associate with changes in the immune system and that characteristics of those events are important in determining the kind of change that occurs.

Selyes (1975) seminal findings suggested that stress globally suppressed the immune system and provided the first model for how stress and immunity are related. This model has recently been challenged by views that relations between stress and the immune system should be adaptive, at least within the context of fight-or-flight stressors, and an even newer focus on the balance between cellular and humoral immunity. The present meta-analytic results support three of these models. Depending on the time frame, stressors triggered adaptive upregulation of natural immunity and suppression of specific immunity (acute time-limited), cytokine shift (brief naturalistic), or global immunosuppression (chronic).

When stressors were acute and time-limitedthat is, they generally followed the temporal parameters of fight-or-flight stressorsthere was evidence for adaptive redistribution of cells and preparation of the natural immune system for possible infection, injury, or both. In evolution, stressor-related changes in the immune system that prepared the organisms for infections resulting from bites, puncture wounds, scrapes, or other challenges to the integrity of the skin and blood could be selected for. This process would be most adaptive when it was also efficient and did not divert excess energy from fight-or-flight behavior. Indeed, changes in the immune system following acute stress conformed to this pattern of efficiency and energy conservation. Acute stress upregu-lated parameters of natural immunity, the branch of the immune system in which most changes occurred, which requires only minimal time and energy investment to act against invaders and is also subject to the fewest inhibitory constraints on acting quickly (Dopp et al., 2000; Sapolsky, 1998). In contrast, energy may actually be directed away from the specific immune response, as indexed by the decrease in the proliferative response. The specific immune response in general and proliferation in particular demand time and energy; therefore, this decrease might indicate a redirection away from this function. Similar redirection occurs during fight-or-flight stressors with regard to other nonessential, future-oriented processes such as digestion and reproduction. As stressors became more chronic, the potential adaptiveness of the immune changes decreased. The effect of brief stressors such as examinations was to change the potency of different arms of specific immunityspecifically, to switch away from cellular (Th1) immunity and toward humoral (Th2) immunity.

The stressful event sequences tended to fall into two substantive groups: bereavement and trauma. Bereavement was associated with decreased natural killer cell cytotoxicity. Trauma was associated with nonsignificantly increased cytotoxicity and increased proliferation but decreased numbers of T cells in peripheral blood. The different results for loss and trauma mirror neuroendocrine effects of these two types of adverse events. Lossmaternal separation in nonhuman animals and bereavement in humansis commonly associated with increased cortisol production (Irwin, Daniels, Risch, Bloom, & Weiner, 1988; Laudenslager, 1988; McCleery, Bhagwagar, Smith, Goodwin, & Cowen, 2000). In contrast, trauma and posttraumatic stress disorder are commonly associated with decreased cortisol production (see Yehuda, 2001; Yehuda et al., 1998, for reviews). To the degree that cortisol suppresses immune function such as natural killer cell cytotoxicity, these results have the potential to explain the different effects of loss and trauma event sequences.

The most chronic stressors were associated with the most global immunosuppression, as they were associated with reliable decreases in almost all functional immune measures examined. Increasing stressor duration, therefore, resulted in a shift from potentially adaptive changes to potentially detrimental changes, initially in cellular immunity and then in immune function more broadly. It is important to recognize that although the effects of chronic stressors may be due to their duration, the most chronic stressors were associated with changes in identity or social roles (e.g., acquiring the role of caregiver or refugee or losing the role of employee). These chronic stressors may also be more persistent, that is, constantly rather than intermittently present. Finally, chronic stressors may be less controllable and afford less hope for control in the future. These qualities could contribute to the severity of the stressor in terms of both its psychological and physiological impact.

Increasing stressor chronicity also impacted the type of parameter in which changes were seen. Compared with the natural immune system, the specific immune system is time and energy intensive and as such is expected to be invoked only when circumstances (either a stressor or an infection; cf. Maier & Watkins, 1998) persist for a longer period of time. Affected immune domainsnatural versus specificwere consistent with the duration of the stressorsacute versus chronic. Furthermore, changing immune responses via redistribution of cells can happen much faster than changes via the function of cells. The time frames of the stressor and the immune domain were also consistent; acute stress affected primarily enumerative measures, whereas stressors of longer duration affected primarily functional measures.

The results of these analyses suggest that the dichotomization of the immune system into natural and specific categories and, within specific immunity, into cellular and humoral measures, is a useful starting point with regard to understanding the effects of stressors. Categorizing an immune response is a difficult process, as each immune response is highly redundant and includes natural, specific, cellular, and humoral immune responses acting together. Given this redundancy, the differential results within these theoretical divisions were remarkably, albeit not totally, consistent. As further immunological research defines these divisions more subtly, the results with regard to stressors may become even clearer. However, the present results suggest that the categories used here are meaningful.

The results of this meta-analysis reflect the theoretical and empirical progress of this literature over the past 4 decades. Increased differentiation in the quality of stressors and the immunological parameters investigated have allowed complex models to be tested. In contrast, previous meta-analyses were bound by a small number of more homogenous studies. Herbert and Cohen (1993) reported on 36 studies published between 1977 and 1991, finding broadly immunosuppressive effects of stress. Zorrilla et al. (2001) reported on 82 studies published between 1980 and 1996, finding potentially adaptive effects of acute stressors in addition to evidence for immunosuppression with longer stressors. It is important to note that meta-analytic findings are bound by the models tested in the literature. As more complex models are tested, more complex relationships emerge in meta-analysis. We next consider some such areas of complexity that should be considered in future psychoneuroimmunology research.

The meta-analytic results indicate that organismic variables such as age and disease status moderate vulnerability to stress-related decreases in functional immune measures. Both aging and HIV are associated with immune senescence and loss of responsiveness (Effros et al., 1994; Effros & Pawelec, 1997), and both are also associated with disruption of neuroendocrine inputs to the immune system (Kumar et al., 2002; Madden, Thyagarajan, & Felten, 1998). The loss of self-regulation in disease and aging likely makes affected people more susceptible to negative immunological effects of stress. Finally, the meta-analysis did not reveal effects of sex on immune responses to stressors. However, these comparisons simply correlated the sex ratio of the studies with effect sizes. Grouping data by sex would afford a more powerful comparison, but few studies organized their data that way. Gender may moderate the effects of stress on immunity by virtue of the effects of sex hormones on immunity; generally, men are considered to be more biologically vulnerable (Maes, 1999), and they may be more psychosocially vulnerable (e.g.,Scanlan, Vitaliano, Ochs, Savage, & Borson, 1998).

It seems likely to us that individual differences in subjective experience also make a substantive contribution to explaining this phenomenon. Studies have convincingly demonstrated that peoples cardiovascular and neuroendocrine responses to stressful experience are dependent on their appraisals of the situation and the presence of intrusive thoughts about it (Baum et al., 1993; Frankenhauser, 1975; Tomaka et al., 1997). Although the same logic should apply to peoples immune responses to stressful experience, few of the studies in this area have included measures of subjective experience, and those reports were limited by methodological issues such as aggregation across heterogeneous stressors. As a consequence, measures of subjective experience were not significantly associated with immune parameters in healthy research participants, with the exception of a modest (r = .10) relationship between intrusive thoughts and natural killer cell cytotoxicity. Psychological variables such as personality and emotion can give rise to individual differences in psychological and concomitant immunological responses to stress. Optimism and coping, for example, moderated immunological responses to stressors in several studies (e.g., Barger et al., 2000; Bosch et al., 2001; Cruess et al., 2000; Segerstrom, 2001; Stowell, Kiecolt-Glaser, & Glaser, 2001).

Virtually nothing is known about the psychological pathways linking stressors with the immune system. Many theorists have argued that affect is a final common pathway for stressors (e.g., S. Cohen, Kessler, & Underwood, 1995; Miller & Cohen, 2001), yet studies have enjoyed limited success in attempting to explain peoples immune responses to life experiences on the basis of their emotional states alone (Bower et al., 1998; Cole, Kemeny, Taylor, Visscher, & Fahey, 1996; Miller, Dopp, Myers, Stevens, & Fahey, 1999; Segerstrom, Taylor, Kemeny, & Fahey, 1998). Furthermore, many studies have focused on the immune effects of emotional valence (e.g., unhappy vs. happy; Futterman, Kemeny, Shapiro, & Fahey, 1994), but the immune system may be even more closely linked to emotional arousal (e.g., stimulated vs. still), especially during acute stressors (S. Cohen et al., 2000). Finally, it is possible that emotion will prove to be relatively unimportant and that other mental processes such as motivational states or cognitive appraisals will prove to be the critical psychological mechanisms linking stress and the immune system (cf. Maier, Waldstein, & Synowski, 2003).

In terms of biological mechanisms, the field is further along, but much remains to be learned. A series of studies in the mid-1990s was able to show via beta-adrenergic blockade that activation of the sympathetic nervous system was responsible for the immune system effects of acute stressors (Bachen et al., 1995; Benschop, Nieuwenhuis, et al., 1994). Apart from these findings, however, little is known about biological mechanisms, especially with regard to more enduring stressors that occur in the real world. Studies that have attempted to identify hormonal pathways linking stressors and the immune system have enjoyed limited success, perhaps because they have utilized snapshot assessments of hormones circulating in blood. Future studies can maximize their chances of identifying relevant mediators by utilizing more integrated measures of hormonal output, such as 24-hr urine collections or diurnal profiles generated through saliva collections spaced throughout the day (Baum & Grunberg, 1995; Stone et al., 2001).

Future studies could also benefit from a greater emphasis on behavior as a potential mechanism. This strategy has proven useful in studies of clinically depressed patients, in which decreased physical activity and psychomotor retardation (Cover & Irwin, 1994; Miller, Cohen, & Herbert, 1999), increased body mass (Miller, Stetler, Carney, Freedland, & Banks, 2002), disturbed sleep (Cover & Irwin, 1994; Irwin, Smith, & Gillin, 1992), and cigarette smoking (Jung & Irwin, 1999) have been shown to explain some of the immune dysregulation evident in this population. There is already preliminary evidence, for instance, that sleep loss might be responsible for some of the immune system changes that accompany stressors (Hall et al., 1998; Ironson et al., 1997).

The most pressing question that future research needs to address is the extent to which stressor-induced changes in the immune system have meaningful implications for disease susceptibility in otherwise healthy humans. In the 30 years since work in the field of psychoneuroimmunology began, studies have convincingly established that stressful experiences alter features of the immune response as well as confer vulnerability to adverse medical outcomes that are either mediated by or resisted by the immune system. However, with the exception of recent work on upper respiratory infection (S. Cohen, Doyle, & Skoner, 1999), studies have not yet tied these disparate strands of work together nor determined whether immune system changes are the mechanism through which stressors increase susceptibility to disease onset. In contrast, studies of vulnerable populations such as people with HIV have shown changes in immunity to predict disease progression (Bower et al., 1998).

To test an effect of this nature, researchers need to build clinical outcome assessments into study designs where appropriate. For example, chronic stressors reliably diminish the immune systems capacity to produce antibodies following routine influenza vaccinations (see ). Yet as far as we are aware, none of these studies has tracked illness to explore whether stress-related disparities in vaccine response might be sufficient to heighten susceptibility to clinical infection with influenza. Cytokine expression represents a relatively new and promising example of an avenue for research linking stress, immune change, and disease. For example, chronic stress may elicit prolonged secretion of cortisol, to which white blood cells mount a counterregulatory response by downregulating their cortisol receptors. This downregulation, in turn, reduces the cells capacity to respond to anti-inflammatory signals and allows cytokine-mediated inflammatory processes to flourish (Miller, Cohen, & Ritchey, 2002). Stress therefore might contribute to the course of diseases involving excessive nonspecific inflammation (e.g., multiple sclerosis, rheumatoid arthritis, coronary heart disease) and thereby increase risk for excess morbidity and mortality (Ershler & Keller, 2000; Papanicoloaou et al., 1998; Rozanski, Blumenthal, & Kaplan, 1999). Another example of the importance of cytokines to clinical pathology is in asthma and allergy, in which emerging evidence implicates excess Th2 cytokine secretion in the exacerbation of these diseases (Busse & Lemanske, 2001; Luster, 1998).

Sapolsky (1998) wrote,

Stress-related disease emerges, predominantly, out of the fact that we so often activate a physiological system that has evolved for responding to acute physical emergencies, but we turn it on for months on end, worrying about mortgages, relationships, and promotions. (p. 7)

Read the rest here:
Psychological Stress and the Human Immune System: A Meta ...

Read More...

Stem Cell Therapy – Kidney -cares

August 4th, 2016 9:36 am

Stem cell therapy is a biotherapy. It brings new hope for people with refractory and incurable diseases. In clinic, it has showed enormous curative effects in treating kidney disease.

Stem cell therapy is the infusion, or injection, of healthy stem cells into your body to replace damaged or diseased body cells. In treating kidney disease,stem cells can differentiate into new cells to replace the impaired renal intrinsic cells, thus reversing impaired kidney structure.

Stem cells are multifunctional cells with the ability of self-renewal and multi-directional differentiation.In certain condition,they can differentiate into various kinds of functioning cells.According to the developmental stage of stem cells,they can divide into embryonic stem cell and somatic stem cell.Based on the developmental potential of stem cells, they can divide into totipotent stem cell,pluripotent stem cell and unipotent stem cell.As they can generate all kinds of tissues and organs,they are called "universal cell".

In kidney disease,the kidneys are impaired significantly,thus resulting in high level of waste products and toxins in body. In such a bad environment,it is not possible for stem cells to differentiate and regenerate.Before stem cell therapy is performed,Blood Purification and Micro-Chinese Medicines Osmotherapy will be used to purify blood by removing all kinds of toxins and waste products from body.

Based on the homing ability,stem cells can differentiate into new cells to replace the impaired renal intrinsic cells.This can regenerate the impaired kidney tissues,thus restoring kidney structure.Thereby,the renal function will be improved.

1. It is widely used to treat diseases and conditions.

2. The best carrier of immunization and gene therapy.

3. Free of toxicity and immune rejection.

4. It can be used before patient understanding pathogenesis completely.

With stem cell therapy,the patients do not need have surgery. So there is no surgical risk in treating disease.As stem cells are primary cells with weak antigenicity on the surface, they will not cause rejection reaction after after being injected into body.

If you want to learn more about stem cell therapy, you can email to kidneycares@hotmail.com .

Stem cell therapy is an advanced technology with the characteristics of safety,non-toxity or low-toxity,and no side effect.The most common clinical adverse reaction is anaphlaxis, but which will recover in several hours by itself.Slightly high fever may occur and the patients do not need to worry about it.

I. Primary kidney disease such as Primary Nephrotic Syndrome, Acute Glomerulonephritis,Chronic Glomerulonephritis,IgA Nephropathy,MPGN,FSGS,and Membrane Proliferative Glomerulonephritis.

II. Renal injury caused by Autoimmune Diseases and connective tissue disease: Lupus Nephritis, Anaphylactic Purpura Nephritis, Glomerular Basement Membrane Disease, Primary Renal Vasculitis, Chronic Infectious Arthritis, Ankylosing Spondylitis, Psoriasis, Sicca Syndrome, Scleroderma, Polymyositis, Dermatomyositis, Behcet's Disease Etc.

III. Renal injury caused by Metabolic Diseases: Diabetic Nephropathy, Hyperuricemic Nephropaihy and hypokalemic nephropathy.

IV. Renal tubular disease and renal interstitial disease: Renal Tubular Acidosis, various kinds of acute and chronic interstitial nephritis;

V. Renal injury caused by infectious diseases: hepatitis B Virus associated glomerulonephritis, hepatitis C Virus associated glomerulonephritis

VI. cardiac function and IV

VII. Cardiorenal Syndrome and Hepatorenal Syndrome

VIII.Renal Injury caused by hypertension.

IX.Hereditary kidney diseases: Alport nephritis, thin glomerular basement membrane disease, Fabry disease etc.;

X. Polycystic Kidney Disease

I. Patient who is allergic to stem cell or patient with serious allergy;

II. pregnant women (woman in lactation period is allowed)

III. Infected patients who is still out of control;

IV. Serious mental illness patient, including patient with tristimania;

V. Severe Hypertension (BP is higher than 160/100mmHg)

VI. Patient with III and IV cardiac function, coronary disease, unstable angina, myocardial ischemia

VII. Patients with obvious renal atrophy

VIII. Patients with severe bleeding tendency

IX. Patients who are taking part in clinical research.

X. Polycystic Kidney Disease

Not all the patients are suitable to the stem cell therapy our hospital own strict selection system to ensure our curative effect.If you are interested in the therapy, you can consult with our online doctor now!

The rest is here:
Stem Cell Therapy - Kidney -cares

Read More...

Page 1,127«..1020..1,1261,1271,1281,129..1,1401,150..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick